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Abstract 
The development of tool compounds for the study of the tetrahydrobiopterin (BH4) metabolic 
network perturbation is of interest especially in the case of oxidative and nitrosative stress genesis. A 
semisynthetic FRET sensor was engineered in order to study competitive dihydropteridine reductase 
(DHPR) inhibition. A high-throughput screen, using the designed sensor, was performed on the 
Prestwick library to discover thirteen new competitively interacting small molecules. Triamterene 
(TRI), ebselen (EBS), adrenosterone (ADR) and deoxycorticosterone (DCS) were found to be the most 
potent inhibitors of this set. Their inhibition potency were assayed in-vitro on four of the members of 
the BH4 metabolic pathway, GTP cyclohydrolase I (GCH1), sepiapterin reductase (SPR), dihydrofolate 
reductase (DHFR) and DHPR. TRI was discovered to be the most active DHPR inhibitor and confirmed 
to be a potent DHFR binder. EBS showed potency in altering GCH1 and SPR catalytic activity probably 
by covalently modifying some of the catalytic cysteine residues. Finally, the drug candidates were 
assayed on adult human dermal fibroblast for their potency to influence the concentration ratios of 
BH4 and 7,8-dihydrobiopterin (BH2). Here, TRI showed to be the best candidate by reducing the 
basal BH4/BH2 ratio of ~15 to unity. This effect is more pronounced than that generated by other 
previously described DHPR inhibitors such as aminopterin. Finally, the observed pterin metabolic 
imbalance generated by TRI makes it a useful compound to investigate the relevance of BH4/BH2 
imbalance.  
 
Keywords: FRET, semisynthetic sensor, dihydropteridine reductase, tetrahydrobiopterin, drug 
screening, triamterene, ebselen, sterone. 
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Résumé 
Le développement de composés « outils » pour l’étude de la perturbation du réseau métabolique 
de la tetrahydrobioptérine (BH4)  est d’intérêt, particulièrement dans le cas de la génération du 
stress oxydatif ou nitrosatif. Un senseur semi-synthétique basé sur l’effet FRET a été créé afin 
d’étudier l’inhibition compétitive de l’enzyme dihydroptéridine réductase (DHPR). Treize nouveaux 
inhibiteurs compétitifs ont été découverts lors d’un criblage à haut capacité ayant été effectué sur la 
librairie chimique Prestwick en utilisant le senseur mentionné. Triamtérène (TRI), ebsélène (EBS), 
adrenostérone (ADR) et déoxycorticostérone (DCS) sont les inhibiteurs possédant le plus haut 
potentiel inhibitif du set découvert. Leur potentiel inhibitif a été étudié sur quatre des enzymes du 
réseau métabolique de la tetrahydrobioptérine (BH4) : la guanosine triphosphate cyclohydrolase I 
(GCH1), la sépiaptérine réductase (SPR), la dihydrofolate réductase (DHFR) et DHPR. Il a été 
découvert que TRI est le meilleur inhibiteur de la DHPR et confirmé qu’il était aussi un inhibiteur 
performant de la DHFR. Altération de la capacité enzymatique de la SPR et de la GCH1 par EBS, 
probablement due à une modification covalente des cystéines catalytiques ou adjacentes aux sites 
actifs, a été démontrée. Finalement, les molécules candidates ont été testées pour leur potentiel à 
alterner la balance métabolique entre BH4 et 7,8-dihydrobioptérine (BH2) dans les cellules 
mammifères de type fibroblaste cutané adulte. La balance métabolique BH4/BH2 basale de quinze a 
été altérée pour une valeur finale de un par TRI. Cet effet est plus prononcé que celui effectuée par 
des molécules inhibitrices de la DHPR, précédemment décrites, comme l’aminoptérine. En 
conclusion, le déséquilibre générée par TRI sur le métabolisme des ptérines dans le model fibroblaste 
peut être d’intérêt afin d’étudier la pertinence du ratio BH4/BH2.  
Mots clés : FRET, senseur semi-synthétique, dihydroptéridine réductase, tetrahydrobioptérine, 
criblage à haut débit, triamtérène, ebsélène, stérone. 
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Chapter 1. Introduction 
This thesis focused on a characterization of the tetrahydrobiopterin metabolic network, and most 
importantly on the role of dihydropteridine reductase, one of its enzymes. We focused on this enzyme as 
tool compounds for its selective inhibition were lacking, yet it plays an important role in recycling 
oxidized cofactor. Furthermore, screening for inhibitors based on FDA approved drugs was of interest in 
order to see if side effects of certain administered drugs could be linked to unwanted interactions with 
the tetrahydrobiopterin network. Consequently, development of a system allowing one to characterize 
the interactions of small molecules with our enzyme of interest was undertaken.  
1.1 The Tetrahydrobiopterin Metabolic Network 
The word pterin comes from the Greek word wing: “pteron”. The pterin family was first described in 
the late 1800s when F. G. Hopkins purified the compound xanthopterin from the English brimstone 
butterfly. Several other pterin derivatives were isolated later on from butterflies and excreted 
substances. Currently, pterins are mostly studied for their biological relevance as metabolites. 
 Tetrahydrobiopterin (BH4), a reduced form of pterin, is the key compound of what will be named 
here the tetrahydrobiopterin metabolic network. Synthetized de novo from GTP by the successive action 
of three enzymes – GTP cyclohydrolase 1 (GCH1), 6-pyruvoyltetrahydropterin synthase (PTPS) and 
sepiapterin reductase (SPR) – the metabolism of BH4 is complex (Fig. 1). The committing step is realized 
at the level of GCH1 where pathway regulation takes place. Although SPR-mediated BH4 biosynthesis is 
favored, there is an alternative BH4 synthesis pathway from 6-pyruvoyl-tetrahydropterin (PPH4) 
involving aldose reductase (AR) B1 and C3, and carbonyl reductase (CR). Double reduction of PPH4 by 
AR-B1, yields in first instance 1’-hydroxy-2’-oxopropyl-tetrahydropterin (2’-oxo-PH4), and then BH4 in a 
nicotinamide adenine dinucleotide phosphate (NADPH) dependent fashion. Furthermore, reduction of 
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PPH4 can, as well, via the action of CR or AR-C3 yield 1’-oxo-2’-hydroxypropyl-tetrahydropterin (1’-oxo-
PH4), from which BH4 can be then accessed by enzymatic conversion through SPR.  
BH4 is a cofactor for the hydroxylases phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TYH) 
and tryptophan hydroxylase (TPH). It acts as an electron donor and feedback regulator for the 
biosynthesis of tyrosine, L-dihydroxyphenylalanine (L-DOPA) and 5-hydroxy-L-tryptophane (5HW) the 
precursor of the neurotransmitter serotonin (Fig1, blue rectangle). During these reactions BH4 is oxidized 
to 4?-hydroxy-tetrahydropterin (4HTP), which enters the recycling pathway. 4HTP can dehydrate in a 
non-enzymatic fashion or via enzymatic catalysis by pterin-4?- carbinolamine dehydratase (PCD) to yield 
6,7-dihydrobiopterin, commonly called quinoid-dihydrobioterin (qBH2). 4HTP can in some conditions 
non-enzymatically isomerize to C7 derivatized analogues.  
Oxidized BH4 can be reformed via 2 routes. In the recycling pathway, dihydropteridine reductase 
(DHPR) reduces qBH2 to BH4 via nicotinamide adenine dinucleotide (NADH)-mediated catalysis, closing 
the recycling pathway loop (Fig 1, green rectangle). Secondly, the salvage pathway is accessed via two 
non-enzymatic oxidations. qBH2, from the recycling pathway, can isomerize to 7,8-dihydrobiopterin 
(BH2). In a similar fashion, 1’-oxo-PH4 can be oxidized to sepiapterin, which is converted in an NADPH-
dependent fashion via SPR or CR to BH2. Dihydrofolate-reductase (DHFR) reduces, in an NADPH-
mediated catalysis, BH2 to BH4 closing the salvage pathway loop (Fig 1, yellow rectangle).  
BH4 biosynthesis is regulated via GCH1 were the enzyme usually resides attached to its feedback 
regulatory protein (GFRP). In this context BH4 acts a a feedback regulator, reducing GCH1 catalytic 
activity while phenylalanine acts as a feedforward modulator. Furthermore, the expression levels of the 
GCH1 is modulated by numbers of compounds such as cytokines. Each part of this pathway and the 
enzymes involved (except AR and CR) are described in greater detail in the following. 
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 BH4 is involved in the regulation of the three nitric oxide synthase (NOS) isoforms. Endothelial NOS 
(eNOS), induced NOS (iNOS) and neuronal NOS (nNOS) all tightly bind BH4 as activator in order to 
promote the production of nitric oxide (NO). In addition, BH4 acts as an electron donor in the production 
of glycerol and aliphatic aldehydes in a reaction involving the enzyme alkylglycerol monooxygenase 
(AGMO). Finally, it has been recently discovered that BH4 is a regulator in the process of monoamine 
neurotransimitter sulfonation. 
Therapeutically, defects in enzymes involved in the BH4 metabollic network can potentially lead to 
disastrous effects. Segawa’s disease, also called DOPA responsive dystonia, is caused by mutations in the 
gch1 gene and often translates in phenotypes such as postural disorders. More common, and involving 
most of the pathway’s enzymes, is the disease phenylketonuria (PKU, further detailed later). PKU is 
caused by an increase of serum phenylalanine and low levels of serontonin, epinephrine and 
norepinephrine. Consequently, patients experience cognitive impairements, dystonia and tremors. 
Furthermore, BH4 availabiliy, particularly increased levels, was shown to influence many sensory 
neurones. Often caused by lesions in the somatosensory system, GCH1 and nNOS upregulation is the 
optimal condition for NO overproduction. It triggers sensitizing nociceptors leading to pathological 
hypersensibility. Finally, evidence also shows that BH4 has implications in the depigmentation disorder 
vitiligo. PCD defficiency leads to formation of 7-substituted pterins reported as inhibitors in the 
biosynthesis of melanin pigments.  
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Fig 1 Tetrahydrobiopterin metabolic network. The network is composed of three main pathways. The de novo BH4
biosynthesis (not framed) is accomplished by principally GCH1, PTPS and SPR. GCH1 catalysis of GTP is the rate limiting step.
It is regulated by feedback and feedforward mechanisms, mediated by GFRP, via the action of respectively BH4 and Phe. On
the transcriptional level GCH1 activity is modulated via several biological molecule but markedly cytokines.BH4 is a cofactor
for, but not exclusively, the hydroxylase family (blue frame) acting as an e- donor. The recycling pathway (green frame)
regenerates the oxidized cofactor 4HTP via the action of PCD and DHPR. Water elimination from 4HTP is principally catalyzed 
by PCD but also occurs non-enzymatically. 4HTP can as well isomerize to C7 pterin isomers. qBH2, the product of dehydration 
by PCD, isomerizes to BH2 entering the salvage pathway (yellow frame). The salvage pathway can be accessed from 
sepiapterin, in case of SPR deficiency. A combination of AR-B1 and AR-C3, as well as CR can compensate for SPR deficiency. 
Compounds from the salvage pathway are reduced back to BH4 by DHFR. 
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1.2 Properties of Pterins 
1.2.1 Nomenclature  
The pteridine bicyclic system is composed of fused pyrazine and pyrimidine rings which are 
commonly numbered as detailed in Fig 2. The molecule 2-amino-4-hydroxy-pteridine is commonly called 
pterin and is found in all the naturally occurring derivatives of this compound. The pterins are divided in 
two subclasses: the conjugated and unconjugated pterins. The folic acid family is part of the conjugated 
pterin subclass since it bears on its C6 a p-aminobenzoylglutamic acid residue (Fig 2 seen in red). All 
other pterins are part of the unconjugated subclass even though most of the naturally-occurring pterins 
carry a side chain on the C6. Indication of the C6 carbon derivatization, as seen for neopterin, 
xanthopterin and sepiapterin, precedes “pterin”. The redox state of atoms 5 to 8 is described by 
prefixing the degree of hydrogenation (Fig 2 seen in blue). The group of biosynthetically obtained pterins 
is called biopterins and often carries as structural feature a hydroxy- or keto-substituted propyl chain1. 
Pterins part of the BH4 metabolic network are only a fraction of naturally occurring forms of the pterin 
family. Nature derivatizes the C6 and C7 positions in myriads of ways2,3 and by forming pterin dimers, like 
drosopterin and pterorhodin, created vast arrays of pigments present mostly in insects4  
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Fig 2 Nomenclature of pterins. The pteridine ring system is composed of fused pyrazine and pyrimidine rings. The figure shows 
the commonly used atoms numbering. Bearing on the C2 and C4 positions an amino and a carboxy group respectively is the 
pterin system. Prefixes are arranged to describe the C6 derivatization (red) and the redox state of N5 to N8 (blue).  
1.2.2 Physicochemical Properties 
Tetrahydrobiopterin is unstable in aqueous buffers and degrades due to aerobic oxidation to qBH2 
and rearranges to BH25. Auto-oxidation proceeds faster at higher pH and oppositely in acidic conditions. 
In certain conditions, complete loss of the 1,2-dihydropropyl moiety takes place6. Experimentally, this 
instability is problematic for quantification of the compound, study of enzymatic processes and study of 
protein-molecule interactions. Other synthetic analogues such as 6-methyl-tetrahydropterin (6MPH4) 
and 6,7-dimethyl-tetrahydropterin (6,7MPH4) have shown better stability in neutral aqueous solutions7,8. 
6MPH4 is roughly two times more stable in aqueous buffer than 6,7MPH49. These compounds are 
usually suitable substitutes for the study of pterin related in vitro experiments. 
Generally, reducing agents such as dithiothreitol (DTT, 1% w/w) or ascorbic acid are used to prevent 
BH4 oxidation. It was shown that BH4 stability in 200 mM trichloro acetic acid (TCA) and 6.5 mM DTT is 
quantitative over 48 h10. Similar solutions are often used to precipitate proteins in cellular experiments. 
Chelating agents such as EDTA or DTPA have also shown to prevent transition metal driven oxidation8.  
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Compound rate of degradation at 25°C 
[BH4], half-life Condition  [BH2], half-life Condition 
20 nM, t1/2 ? 48 h 300 mM TCA, 6.5 mM DTE11 20 nM, t1/2 = 3.3 h 300 mM TCA, pH: 0.8911 
20 nM, 0.25 nM/h 50 mM phosphate, 6.5 mM DTE, pH:7.411 20 nM, t1/2 = 4.73 h 300 mM TCA + 6.5 mM DTE, 
pH: 0.8911 
30 ?M, t1/2 = 10 min 100 mM phosphate, pH: 6.85 20 nM, t1/2 = 79.7 h 50 mM phosphate, pH: 7.411 
30 ?M, t1/2 = 6.5 min 100 mM phosphate, pH: 8.25 20 nM, t1/2 = 113 h 50 mM citrate, pH: 611 
30 ?M, t1/2 = 38.5 min 50 mM triethanolamine/HCl, pH: 712 20 nM, t1/2 = 6.6 h 50 mM citrate, pH: 311 
100 ?M, t1/2 ~ 30 min 100 mM phosphate, 0.4 mM DTPA, pH 7.410   
[qBH2], half-life Condition [6,7MePH4], half-life Condition 
30 ?M, t1/2 ~ 1.3 min 100 mM phosphate, pH: 6.85 1 mM, t1/2 = 120 min Chloroacetic acid, pH: 38 
  1 mM, t1/2 = 25 min HEPES, pH: 8
8 
  1 mM, t1/2 = 2 min NaOH, pH: 13
8 
[6MqPH2], half-life Condition [6,7MqPH2], half-life Condition 
10 ?M, t1/2 ~ 1.7 min 100 mM phosphate, pH: 6.813 100 ?M, t1/2 ~ 45 s 100 mM phosphate, pH: 6.89 
10 ?M, t1/2 ~ 27.7 min 100 mM Tris, pH: 6.813 100 ?M, t1/2 ~ 14 min 100 mM Tris, pH: 6.89 
Table 1 Half-life of degradation of different pterins at 25 °C. The rate of endogenous and synthetic pterins is presented has 
half-life (t1/2) for first order reactions and with their respective units for zero order reaction. Concentration and conditions are 
indicated as they influence the degradation rate.  
 
BH2 and other dihydro-analogues have a greater aqueous stability but will still degrade or oxidize 
relatively slowly in acidic conditions. Biopterin is the main degradation product of BH2, in aqueous 
buffers, regardless of the pH. It has been shown that both BH4 and BH2 stability, independent of the 
conditions, is concentration dependent as well. In acidic conditions, traditionally used for protein 
precipitation prior analysis, BH2 half-life was determined to be greater than 2.5 h11. The degradation 
half-life of several pterins is reported in Table 1. 
Oxidized pterin rings have three characteristic UV absorbance bands around 230, 280 and 330nm5,14. 
BH4 is non-fluorescent, while BH2 is about half as brightly fluorescent as biopterin. Pterin also possesses 
very strong fluorescence. All of the fluorescent pterins can be excited around 350nm and emit around 
450nm. A summary of the absorbance and fluorescence properties is given in Table 2. 
Relevant to the method used later for the quantification of pterins are their electrochemical 
properties. BH4 was shown to possess an oxidation potential of E = 270 to 300 mV vs NHE, a potential 
sufficient to reduce several biologically relevant molecules15 and ferric iron8. Notably, BH4 reduces 
rapidly cytochrome-c (E(Fe+3/Fe+2) = 260 mV, k = 4.4E3 M
-1·s-1) and cytochrome-b5 (E(Fe+3/Fe+2)= 0 mV, k = 0.2 
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M-1·s-1) potentially impacting mitochondrial functions16. The potential needed to oxidize BH2 was 
reported to be 820mV vs NHE.  
Spectroscopic characteristics of certain pterins 
Name Absorbance 
UV ext. coef. [M
-1
 cm
-1
] @ wl. [nm]; buffer 
Fluorescence 
 (quant. yield;ext[nm];em[nm];cond) 
BH4 14300 @ 265; 0.1 M HCl17 
5500 @ 295; 0.1 M HCl17 
N.D. 
BH2 26120 @230; 0.1 M phosphate, pH: 6.85 
11330 @ 279; 0.1 M phosphate, pH: 6.85 
6820 @ 330; 0.1 M phosphate, pH: 6.85 
13510 @257; 0.1 M HCl5 
4850 @367; 0.1 M HCl5 
5.3e-2;350;450;-14 
Biop 11000 @ 247; 0.1 M HCl18 
5200 @ 350, 0.1 
0.1, 350;450;-14 
0.16, 360;450;pH: 3 
PH2 10850 @ 275; 0.1 M phosphate, pH: 6.85 
5400 @ 325; 0.1 M phosphate, pH: 6.85 
13670 @259; 0.1 M HCl5 
2180 @321; 0.1 M HCl5 
1890 @370; 0.1 M HCl5 
- 
Pterin 11200 @ 235; AcOH, pH: 519 
12300 @ 270; AcOH, pH: 519 
6000 @ 338; AcOH, pH: 519 
2683 @ 324; phosphate, pH: 6.820 
0.33; 360; 450; acidic 
XH2 1911 @ 324; phosphate, pH: 6.820 - 
Neopterin  0.16, 360;450;pH: 3 
Table 2 Spectroscopic characteristics of certain pterins. Various pterins absorbances at specific wavelength and conditions 
as well as quantum yields are given. N.D.: not detectable. Some conditions are not specified and are replaced by a dash.  
 
Two electrochemical oxidation mechanisms, dependent on the experimental setup (pH variation, 
glassy carbon electrode vs polished carbon surface) were proposed. Reports diverge on the mechanism 
of electro-oxidation of BH4 to biopterin via qBH2 and BH2. Some authors argue that each oxidation step 
is a two electron process21,22 while others present a single electron transfer forming a cation radical 
followed by a rapid chemical rearrangement15 (Fig 3). All agree though that the qBH2 to BH2 
isomerization cannot be forced by applying electrical potential and proceeds with a half-life of roughly 87 
s.  
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Fig 3 Electrochemical oxidation scheme of tetrahydrobiopterin. Two oxidation mechanisms have 
been proposed. One proceeds in a single step two-electron fashion, whereas the other proceeds in a two-
step single-electron way. The latter mechanism is believed to form transient cationic radicals rapidly 
rearranging to form the oxidized analogue. qBH2 cannot be forced to isomerize to BH2. 
 
1.3 Enzymes of the BH4 Metabolic Network 
1.3.1 Dihydropteridine reductase (DHPR)  
1.3.1.1 History of Discovery 
S. Kaufman, in 1957, was studying the conversion of phenylalanine to tyrosine23 and discovered that 
this reaction required two enzymes purified from liver, NADPH and oxygen to take place. In the same 
year, he suggested that an unknown cofactor might be implied in this conversion24. Following, he 
stipulated correctly, that this previously suggested cofactor, if missing, would lead to phenylketonuria25. 
The system was further described and in 1958 he was able to show that one of the two enzymes was a 
reductase. This enzyme promotes an interaction between the cofactor and NADPH and would not 
require oxygen26. It was noted that the cofactor could belong to the pteridine family based on the 
observation that it possessed high nitrogen content and on the activity of tetrahydrofolate in the assay27. 
Relying on this information, Kaufman tested 6,7-dimethyltetrahydropterin (6,7MBH4), and 6-
methyltetrahydropterin (6MBH4) as cofactors in the system showing that the later was the most 
efficient7. In 1959, the roles of two enzymes were attributed showing that the second enzyme was an 
hydroxylase that had no interaction with NADPH and converted phenylalanine to tyrosine only in the 
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presence of BH4. It was also confirmed that the reductase keeps, in the presence of NADPH, the BH4 in 
its active form28,29. Between 1963 and 1966, Kaufman described the reductase cofactor further and, by 
observing high activity of the compounds sepiapterin and reduced biopterin concluded that the 
reductase enzyme cofactor is a dihydropteridine in its quinoid form30,31,32. He also discarded the 
possibility that DHFR might act as the reducing enzyme through the inhibition of both DHFR and DHPR 
enzymes by aminopterin (APT)33. The reductase enzyme was named DHPR in a later paper34 and it was 
discovered by Nielsen et. al. in 1969 to have a much higher affinity for NADH13. These results marked the 
first milestone in the understanding of the BH4 recycling pathway. 
 
Fig 4 DHPR structure: (A) Surface representation of the active site. NADH is represented in orange and its C4, colored in light 
green. Points towards the active site cleft (red and green). (B) Cartoon representation of DHPR. ?-sheets are represented in red 
and form the backbone of the enzyme. The ?-helices are colored in blue with, in dark blue, the helices responsible for the DHPR 
homodimer formation. Pdb reference : 1DIR 
 
1.3.1.2 DHPR Structure 
Isolated from rat liver, a first DHPR crystal structure with its natural cofactor NADH was proposed in 
1992 by Varughese et. al.35. Obtainment of this structure was preceded by crystallization attempts36 and 
primary structure studies on several homologues37. A year later the human DHPR structure along with its 
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full characterization was published38. Later on several homologues were crystalized but so far no 
structure has been reported with BH2 or with the natural cofactor qBH239,40 due to the instability of the 
cofactor.  
DHPR is a member of the short chain dehydrogenase/reductase family41, a family presenting a 
common conserved Rossmann-type dinucleotide fold. As seen in Fig 4, the DHPR core is predominantly 
composed of ?-sheets (red) whereas ?-helices (blue) flank the core to compose the outer shell. This 
protein fold is common in enzymes such as alcohol42, malate43 and lactate dehydrogenase44 were the 
dinucleotide binding domain, composed of 150 to 200 amino acids, is conserved and a second, substrate 
specific, binding domain has evolved to fulfill its catalytic function. The naturally occurring enzyme 
structure consists of a homodimer bound to two NADH molecules35,38. The dimeric structure is stabilized 
by a 4 ?-helix cluster (Fig 4 dark blue), a common structural motif in these proteins45,46.  
The DHPR active side is a U-shaped surface channel where qBH2 docks. The molecule qBH2 is 
reduced by the transfer of the pro-S hydrogen of NADH to its N547 (Fig 4A). A sequential substrate 
binding mechanism was reported48 were first NADH binds to DHPR followed by qBH2. BH4 is then 
released first followed by NAD+. This mechanism is corroborated by the observation that DHPR was not 
able to bind to APT-agarose columns in the absence of NADH49 and was further confirmed in our 
experiments. Further details on how qBH2 might bind are given in the results section. 
 
 
Fig 5 Structure of various DHPR substrates. DHPR has a weaker affinity for the two pyrimidino derivatives 
compared to pterin derivatives showing the importance of the closed pyrazine ring. 
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1.3.1.3 Substrates and Inhibitors 
 As previously described, the natural substrate qBH2 and cofactors NADH of DHPR are 
characterized with the respective Kd ?20 nM50 and KM = 0.15 ?M38. The Kd of NADH is roughly 55-fold 
and 2000-fold lower than that of NADPH (Kd = 2.02 ?M) and NAD+ (Kd ?0.1 mM38), respectively. 
Furthermore, it is expected for the enzyme to be bound, in the cytosol, to NADH as the respective 
concentration is 5000 folds above the Kd. It is of importance when later designing a sensor which will be 
bound to NADH as to keep relevance with respect to the cellular conditions. Several synthetic derivatives 
of pterin are substrate analogues, see Table 3. As previously discussed, derivatization on both C6 and C7 
are to a certain extend accepted by the enzyme. It was shown that methyl groups can saturate C6 & C7 
of the pterin. Furthermore, the pyrazine ring does not need to be closed for a compound to be a 
substrate. As seen in Fig 5, several synthetic compounds were shown to be reduced even when the 
substrate lacked C6 and C7 or the C7-N8 bond51. It was reported that the KM value for 2,6-diamino-5-
iminopyrimidin-4-one is an order of magnitude higher than the KM value for quinoid 6,6,7,7-
tetrahydropterin supporting the notion that a conserved pyrazine ring improves binding51.  
Substrates   
Name Kd / KM [?M] [Cytoplasm] [?M] 
NADH Kd = 0.02 99 ± 37 52 
NAD+ Kd ? 100 230 ± 111 53 
NADPH Kd = 2.02 100 ± 50 54 
qBH2 KM = 0.15  
BH4 Kd = 30  
6,7-dimethyl- quinoid-dihydropterin KM = 13.4 
55  
6-methyl-quinoid-dihydropterin KM = 19.4 
13  
Inhibitors   
Name Ki [?M]  
Amethopterin (Methotrexate - MTX) 38  
Aminopterin (APT) 20  
2,4-Diaminopteroic acid 29.5  
2,4-Diaminopteroic-7,8-dihydropteroylglutamic acid 23  
Quinoid 2,4-Diaminopteroic-7,8-dihydropteroylglutamic acid 22  
 
 
 
 
Table 3 Summary of DHPR substrates and inhibitors. 
Relevant DHPR substrate KM and Kd as well as known 
competitive inhibitors are given. If not stated values come 
from the reference 56. The structure of the inhibitors MTX and 
APT is given. 
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As previously discussed, quinoid forms of pterin are oxidized non-enzymatically to their 7,8 
dihydropteridin forms becoming a DHFR substrate. Several DHPR competitive inhibitors were reported 
and are summarized in Table 3. The Ki values reported for these inhibitors were obtained on liver 
extracts (rat and sheep). Additionally, a large amount of studies have been made to determine the 
thermodynamic and kinetic values for the interaction of DHPR and its substrates. Reported values vary a 
lot due to the nature of the experiment used and the purification from tissues of different species. 
Several non-competitive or uncompetitive inhibitors were reported57,58,59 but will not be further 
described here.  
1.3.2 GTP Cyclohydrolase 1 (GCH1) and GCH1 Feedback Regulatory Protein 
(GFRP) 
1.3.2.1 History of GCH1 & GFRP Discovery 
GCH1 was first purified in 1968 from E.coli cultures when A. W. Burg and G. M. Brown realized that 
an enzyme incorporated GTP in the pteridine moiety of folic acid and was releasing formic acid in the 
process60. It was hypothesized correctly that GCH1 was solely responsible, for the complex, multistep, 
catalysis of 7,8-dihydroneopterin triphosphate (H2NTP). A year later, G. M. Brown found evidence of the 
Amadori rearrangement taking place in the GTP ribose prior to pterin ring closure61. Mechanistic details, 
particularly on the hydrogen transfer, were later solved by Bracher et al.62. But it was only in 1995 when 
the first GCH1 crystal structure was presented by Nar that the role of some of the amino acids could be 
established63,64. In the meantime Harada pointed out correctly that GCH1 feedback inhibition by BH4 was 
due to another element. The p53 peptide, called now GFRP, was isolated and characterized65. Value 
disagreement during an experiment comparing GCH1 rates isolated from rat liver or purified from E. coli 
– lacking the BH4 metabolic pathway – in the presence of allosteric modulators shed light on the 
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regulatory peptide presence66. Finally, Maita reported in 2002 and 2004 crystal structures of GFRP bound 
to GCH1, setting a milestone in the research on GCH1-GFRP interaction and mechanism67,68. 
1.3.2.2 Structure and Mechanism 
GCH1 is a 260 kDa torus-shaped homodimer of homopentamers. Each pentamer is formed via a 20 
residues antiparallel ?-sheet association combining face-to-face to form the homodecamer (Fig 6 A,C). 
GCH1 possesses 10 independent active sites each located at the interface of 3 monomers and bound to a 
zinc ion (Fig 6 D). Binding of GTP is highly specific and no other nucleotides were reported as suitable 
substrates. A KM of 75 ?M for GTP was reported independent of GFRP binding69. His179 initiates the GTP 
conversion reaction by interacting with the guanidine N7 while His112 would H-bond to the ribose 
oxygen (Fig 6 E). Ring opening and formic acid elimination is mediated by the zinc ion coordinated by 
Cys110 and Cys18170. Finally, proton exchange and ketone formation, allowing ring closing via Schiff’s 
base dehydration, is mediated by Ser135 to yield H2NTP63.  
GFRP is a homopentamer of 50 kDa and part of the ?-propeller family, where each subunit is 
composed of 83 amino acids71. Two GFRP units interact with one GCH1 homodecamer, binding at the top 
and bottom of the torus yielding a 360 kDa complex (Fig 6 B, C). A Kd of 8 to 15 nM has been reported 
for this interaction independent of the presence of substrates72,73. Three loops from one GFRP subunit 
interact with two GCH1 subunits creating an accessible cleft for phenylalanine and BH4 to bind.  
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Fig 6 GCH1 & GFRP structure and catalytic mechanism. (A) Top view of the GCH1 homodecamer. (B) Top view of one GFRP 
homopentamer. (C) Side view of the GCH1-GFRP complex. GCH1 subunits are shown in cold colors. GFRP subunits are shown in 
warm colors. (D) Zoom on the binding sites of GTP, BH4 and Phe. GTP (pink, right) is bound between 3 subunits close to the Zn 
ion (yellow dotted). BH4 (green, center) and Phe (orange, left) are bound at the interface of GFRP and GCH1. The model is made 
by the alignment of three structures: Phe containing structure: 1IS7; GTP containing mutant: 1A8R; BH4 containing structure: 
1WPL. (E) Catalytic mechanism for the transformation of GTP to H2NTP. 
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1.3.2.3 Regulation 
GCH1 being involved in both the BH4 metabolic network and the folate synthesis is a strategic point 
for regulation. At the transcriptional level, strong up-regulation has been observed in the case of 
inflammatory response by cytokines74 or by administration of lipopolysaccharides or estradiol. In 
different combinations, interferon-? (INF-?)75,76, tumor necrosis factor-? (TNF-?)77, interleukin-1? (IL-
1?)78, nerve growth factor (NGF)79, lipopolysaccharides (LPS)80,81, estradiol benzoate82 (EB) and H2O283 
have all shown to possess some influence on GCH1 transcription levels. GCH1 and BH4 levels were 
decreased in sympathetic neurons (SPN) by leukemia inhibition factor (LIF) and ciliary neurotrophic 
factor (CNTF)84. At the protein level, phenylalanine, BH4 and guanoside are able, via interaction with 
GFRP, to modulate the enzyme’s kinetic properties. However, effect of single cytokines in the 
modulation of GCH1 activity seems case dependent as reports differ with respect to tissues, species and 
culture methods78. Table 4 summarizes the magnitude of GCH1 regulation by several cytokines.  
Experimentally, TNF-? in combination with INF-? have been used to generate high pterin yielding 
cellular models. Such an activation method is commonly used and convenient when studying the effects 
of drugs on metabolites. At high GCH1 expression level, the enzyme is not the bottle-neck anymore, 
leading to excretion of overflowing H2NTP and neopterin from cells85,86.  
Combination INF-? TNF-? IL-1?  NGF 2-4x LIF (SPN) ~0.1x 
INF-? 7-40x (VEC) 300x (VEC) -  LPS 2-3x (rat) CNTF (SPN) ~0.2x 
 TNF-? 5x (VEC) 10x (VEC)  EB 2x (rat brain)   
  IL-1? 5x(VEC)  H2O2 4x   
Table 4 GCH1 regulation by cytokines and compounds. The table presents the rates of activation of GCH1 alone or in 
different combinations. The values are case dependent and vary with respect to tissues and organisms. 
 
The GCH1-GFRP complex is also subject to allosteric regulation. As described before, phenylalanine is 
able to bind, with a Kd of ~100 ?M, at the GFRP-GCH1 interface and stimulates GTP conversion 2-fold87. 
It was also shown to increases the affinity of GFRP for GCH172. Oppositely, bound BH4 will act as an 
inhibitor, lowering the Vmax for the formation of H2NTP but leaving the affinity for GTP unchanged65. 
The Kd for BH4 was reported to be 4 ?M with maximal inhibition at 7 ?M. The binding of both BH4 and 
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phenylalanine are known to be pH sensitive and are given here at physiological pH. Furthermore, 
phenylalanine is able to overcome the inhibitory effect of BH4 by restoring the GCH1-GFPR complex in an 
active form65. GCH1 activity was shown to be modulated by post-translational modification. 
Phosphorylation on residues Ser-167 (in the rat sequence, conserved with human)88 by protein kinase C 
was reported to elevate BH4 levels concomitant with an increased GCH1 activity. Furthermore, GCH1 
activity as well as GCH1-GFRP complex formation are believed to be influenced by its N-terminus. 
Cleavage on the first 11 residues can be performed but as for now no solid evidence points towards a 
regulatory feature72,89.  
Few inhibitors have been developed and only the weak 2,4-diamino-6-hydroxypyrimidine (DAHP, IC50 = 
0.3 mM) compound has been reported to selectively inhibit GCH1 in a GFRP dependent fashion90,69. 
1.3.3 6-pyruvoyltetrahydropterin synthase (PTPS) 
1.3.3.1 History of the Discovery 
First mentions of PTPS appeared around 1980 as a Mg2+-dependent “phosphate-eliminating enzyme” 
known to convert H2NTP91. The first human homologue purification and characterization took place in 
198692 incorrectly describing the enzyme as a homotetramer of 83 kDa. However, the authors stated 
correctly that phosphate elimination and dual hydroxyl oxidation proceeded in an NAD(P)H-independent 
fashion. Several purification attempts, on now recombinant proteins, successfully led to the amino acid 
sequence and subunit size identification93 as well as description of the homodimer of homotrimer 
organization94. In the same year, the PTPS crystal structure was obtained describing a yet unusual type of 
subunit association and active site95. Complete mechanistic description and involvement of H2NTP 
proximal Cys, Glu and Zn was then described by Ploom et al.96. 
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Fig 7 Structure and catalytic mechanism of PTPS. (A) Top view of the homo-hexamer. (B) Side view and zoom on the active 
site. In the zoom, subunit A is shown in blue while subunit B is shown in red. Pdb references : 1B66 (BH4 bound subunit) and 
3I2B (Homohexamer). (C) Catalytic mechanism of the formation of PPH4 from H2NTP.  
1.3.3.2 Structure and Mechanism 
PTPS is a homohexamer of 93 kDa, structured as a homodimer of homotrimer. Each trimer is, in its 
center, organized as a 12-stranded antiparallel ?-barrel while ?-helices form the outer rim. Three 
subunits, 2 from one trimer and 1 from the other (A, A’ & B), form the active site, yielding 6 active sites 
per enzyme (Fig 7 A,B). Interestingly, this type of quaternary structure had been observed for GCH1 and 
already been described64. Mechanistically, GluA107, as pterin-anchor, will facilitate H2NTP binding to the 
active site via hydrogen binding with N2 and N3 of H2NTP (Fig 7 B, zoom). The first step, mediated by 
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CysA42, is the abstraction of the C1’ proton97. This residue is activated by His B89 and Asp B88 forming a 
catalytic triad. The zinc ion coordinates the hydroxyl moieties of C1’ and C2’ from H2NTP in a cis-
conformation increasing acidity of the C1’ and C2’ hydroxy protons96. Ketone formation and triphosphate 
elimination is performed via the action of Glu A133 and Cys A42 to yield PPH4 (Fig 7, C). Wild-type PTPS 
KM for H2NTP was reported to be 8 ?M. In the endothelial model, IL-1? – and to a lesser extend TNF-? – 
mediated PTPS upregulation has been demonstrated. Roughly three fold increase of PTPS activity was 
reported, decreasing neopterin leakage in this cellular model98. 
1.3.4 Sepiapterin Reductase (SPR) 
1.3.4.1 History of the Discovery 
Matsubara et al. first described SPR in the early 60-ties99. They realized that sepiapterin was being 
converted to BH2 via the action of NADPH. Katoh, later on pointed out the capacity of SPR to slowly 
oxidize in the presence of NADP+ some L-erythro and L-threo-dihydroneopterin, but not the D- isomers, 
as well as BH2. These observations shed light on the importance of the stereochemistry of the C1’ 
functional groups 100. In 1982, Sueoka described the molecular properties of the enzyme, a homodimer 
of molecular weight of ~55 kDa101. Two years later the same group, along with observations related to 
H2NTP conversion to PPH4102, proposed the implication of SPR in the biosynthesis of BH4103. These 
findings were refined later by Smith and Katoh correctly describing the conversion from PPH4 to BH4 via 
1’ and 2’-oxo-PH4 and non-enzymatic oxidation of 1’-oxo-PH4104,105. In the 90s the amino acid sequence 
and roles in catalysis as well as the crystal structure were reported, concluding the main description of 
SPR106,107,108. 
1.3.4.2 Structure and Mechanism 
SPR is a Rossmann fold containing enzyme structured as a 56kDa homodimer of 261 residues each. It 
is part of the short chain dehydrogenase/reductase family107. The dimer is stabilized by the formation of 
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four helix bundle maintained by hydrogen bonds, and interacting charges (Fig 8A, shown in darker 
colors). The assembled dimer possesses an antiparallel conformation. Similar to DHPR and to enzymes 
possessing a Rossmann fold, the nicotinamide ring is positioned at the C-terminal end of the ?-strands 
(Fig 8B). SPR pterin substrates are anchored in the active site with their guanidino moiety oriented 
towards Asp258 and Gly200. In such conformation the C1’-carbonyl is oriented in close proximity to 
NADP C4’N and Tyr171 OH. Similarly to the hydride transfer mediated by Tyr151 on the qBH2 N5 in the 
case of DHPR, Tyr171 plays a role of mediator in the C1’ ketone reduction. Sepiapterin C1’ carbonyl atom 
has been reported to be placed at 3.2 Å from the nicotinamide C4.  
 
C 
 
Fig 8 Structure and catalytic mechanism of SPR: (A) Mouse SPR dimer structure. Helices stabilizing the homodimer are 
shown in dark. NADPH is shown in orange and sepiapterin in grey. (B) Active site zoom. The pdb references were 1SEP and 
1OAA. (C) Catalytic mechanism for the conversion of PPH4 to 1’-oxo-PPH4.  
 
 SPR has been shown to be a promiscuous enzyme able to reduce, in a NADPH dependent fashion, 
various carbonyl and aldehyde functions103,109. However, in the case of BH4 biosynthesis, it catalyzes the 
PPH4 C1’ ketone reduction first, taking on the role of reductase. The reduction is stereospecific with the 
hydride transfer taking place on the C1’ carbon followed by the abstraction of the Tyr171 proton (Fig 8C). 
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Lys175 is believed to orient the nicotinamide ring. SPR then takes on the role of an isomerase and 
catalyzes the formation of the C2’ hydroxy group. This reaction is pursued in a NADPH independent way, 
through the formation of an enediol intermediate stabilized by the tyrosinate residue110. The newly 
formed C1’ ketone is finally reduced to yield BH4. As previously explained, BH2 formation from 
sepiapterin is catalyzed by SRP in the salvage pathway. Two cysteine residues (Cys160 and Cys172) are 
believed to act as additional proton sources and isomerization mediators.  
In pathological cases of SPR deficiency, de novo production of BH4 can be performed via AR and CR 
through the salvage pathway111,112. Homeostasis can be maintained via this pathway as it is believed that 
the recycling pathway is dominant over the de novo113. Generally, PKU symptoms, in newborns with SPR 
deficiency, are not observed. 
1.3.4.3 Substrates and Inhibitors 
As previously mentioned SPR possesses several substrates. Sepiapterin’s KM was measured to be 
between 15 and 41 ?M99b, 100, 114,101. SPR most active dinucleotide, NADPH, has a KM between 1 and 14 
?M 100, 114,101 while KM for NADH is roughly a quarter to a half of the natural cofactor99b. Affinity for NADH 
was measured in house to be Kd = 1 ?M. Furthermore PPH4, 1’ and 2’-oxo-PH4 were found to have KM of 
respectively 2, 8, and 7 ?M104.  
N-acetyl serotonin (NAS) has been shown to be a competitive SPR inhibitor118. It was the first 
reported potent drug and has often been used as molecular benchmark. Melatonin, serotonin and L-
norepinephrine also act as weak binders. A derivative of NAS, termed SPRi3 was developed by structure-
activity relationship and presented a 25-fold increased SPR inhibitory potential vs NAS.115 More recently, 
xanthurenic acid, part of the kynurenine pathway was reported as being as well an SPR inhibitor117. 
Furthermore, a yeast-three-hybrid study revealed that sulfa drugs were off-target SPR inhibitor. Several 
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sulfa drugs have shown in-vitro and in-vivo potency116,119. All the inhibitory values are reported in Table 
5. 
Compound In-vitro In-vivo 
IC50 Ki IC50 
NAS 1.9 ?M,1153.1 ?M116, 3.8 ?M117 0.2 ?M118 54 ?Ma,115 
Melatonin  30 ?M118  
Serotonin  2.3 mM118  
L-norepinephrine  3.4 mM118  
SPRi3 74 nM 115  5.2 ?Ma,115 
Sulfasalazine 23 nM116, 7 nM119  Non permeablea,119 
N-acetyl sulfapyridine 290 nM116   
Sulfapyridine 480 nM116, 82 nM119  201 ?Ma,119 
Mesalamine 370 ?M 116   
Sulfathiazole 14 nM 119  23 ?Ma,119 
Sulfamethoxazole 19 nM119  59 ?M119 
Sulfamethizole 19 nM119   
Phthalylsulfathiazole 24 nM119   
Chlorpropamide 36 nM119   
Sulfadiazine 43 nM119   
Glibenclamide 82 nM119   
Tolbutamide 92 nM119   
Sulfamethazine 16 ?M119  Non permeable a,119 
Xanthurenic acid 150 nM117   
a: IC50 in-vivo measured by total BH4 biosynthesis 
Table 5 Summary of known SPR inhibitors. Some values for drugs inhibition potential is given for both in vitro 
and in vivo experiments 
 
1.3.5 Dihydrofolate Reductase (DHFR) 
1.3.5.1 History of the Discovery 
DHFR has mostly been studied for its involvement in the folic acid metabolism. Starting in the late 
50-ies, the research on DHFR was closely linked to discoveries of PAH and DHPR30. Early research showed 
that extracts of horse liver lysates were able to convert folic acid to tetrahydrofolate (FH4)120. It was 
discovered in 1956 that a dinucleotide was needed to perform this conversion121. In the two following 
years the terms “folic acid reductase” and “dihydrofolic reductase” were mentioned, and it was 
demonstrated that the reaction using an enzyme partially purified from chicken liver extract, could be 
inhibited by APT and MTX122,123,124,125. Detailed stoichiometry and efficient cofactor activity of NADPH 
were also described. In 1963, Morales et al. established that 6MPH2 was a cofactor of relatively low 
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activity compared to FH2 and correctly postulated, based on S. Kaufmann’s work, that BH2 could be a 
cofactor126,127. DHFR due to its small size and stability was relatively quickly crystalized128 and in 1988, 
Oefner et al. reported the human recombinant crystal structure of DHFR (hDHFR) in complex with 
dihydrofolate (FH2)129. Mctigue et. al. later proposed that only the vertebrae structure bound to a pterin 
cofactor130. Finally, the notable interspecies differences of the catalytic mechanism were described in the 
90s131,132. 
 
 
 
Fig 9 Structure of DHFR. (A) Superimposed structures of hDHFR (blue) in complex with NADP+ and folate, and cDHFR (red) 
with biopterin and NADP+. Loops are shown in pale tints, ?-helices in mid tints and ?-sheets in dark. Folate is shown in black and 
biopterin in grey. Reference structures are hDHFR = 4M6K, cDHFR = 1DR1. (B) Focus on the biopterin binding pocket in cDHFR. 
Biopterin is anchored by Glu30 and stabilized by a two water H-bonding lattice with Glu30 and Trp24. Phe34 stabilizes the 
biopterin orientation by ?-? stacking. Biopterin C6 in in close proximity to NADP+ for optimal hydride transfer. (C) Overall 
comparison of the organization of ?-helices and ?-sheets of DHFR and DHPR.  
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Structure and Mechanism 
A large percentage of research on DHFR structure and mechanism has been performed on the E.coli 
homologue (eDHFR)133. Furthermore, no structure of hDHFR exists in complex with a pterin molecule. 
Therefore, a chicken liver DHFR (cDHFR) structure130 complexed with biopterin and NADP+ is used in 
comparison to hDHFR complexed with folate and NADP+ to describe the enzyme structure134. DHFR is a 
18 kDa monomer possessing an ?/? structure. Eight ?-sheets are flanked by 4 ?-helices with a backbone 
similar to DHRP due to their respective NAD-dependency135. The connectivity of the ?-helices with 
respect to the ?-sheets diverges in DHFR in comparison to the traditional Rossmann-fold35 (Fig 9,C). 
Nevertheless, as seen in Fig 9,A the crystal structures are very similar. As a general observation, biopterin 
(shown in grey) and FH2 (shown in black) pterin rings overlap while their side chains orientations differ. 
NADP+ adenine moieties are slightly tilted while the two nicotinamide moieties are aligned in close 
proximity to the substrates. Similarly to PTPS and SPR, Glu30 anchors biopterin by H-bonding with N2 
and N3 (Fig 9,B). Phe34 stabilizes the biopterin conformation via ?-? stacking. Furthermore, a water 
molecule present in other DHFR crystal structures plays a role in extending the H-interaction lattice 
formed by Trp24 and Glu30. Additionally, another water molecule orients the side chain away from the 
NADPH nicotinamide ring. NADPH hydride donor C4 is in 3.3 Å proximity with BH2 C6 a similar value to 
what is observed in dinucleotide dependent reductases. The same interactions were reported for hDHFR 
complexed with folate136. Furthermore, it has been shown that eDHFR and hDHFR possess a Met20 loop 
(Fig 9,B loop in the first plane containing Trp24)134. This loop adopts in hDHFR a single locked 
conformation allowing the enzyme to access to two mechanistic catalytic pathways131. However, in 
eDHFR the loop adopts both a closed (eDHFR:NADPH) and occulted (eDHFR:NADP+:Folate) conformation. 
To our knowledge, no detailed kinetic studies have been made on the pterin catalytic cycle in hDHPR. It 
can be assumed that the overall kinetic cycle for the folate catalysis is conserved but the kinetic values 
change. The hDHFR:NADP+:FH4 complex is a branch point in the FH4 catalytic cycle as either NADP+ or 
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FH4 can dissociate leading to two different catalytic pathways (Fig 10)132. Generally the rate limiting 
steps are the substrates dissociation as conversion from FH2 to FH4 has been shown to be fast and fairly 
unidirectional. The cycle starting by NADP+ dissociation has been reported to account for roughly 65% of 
the total reaction turnover. 
 
Fig 10 hDHFR catalytic cycles with FH4. hDHFR possesses two catalytic cycles, 
branching at the substrates dissociation in the hDHFR:NADP+:FH4 complex. The upper 
cycle, not present in eDHFR, exchanges 35% of the cofactors. The bottom cycle, 
present as well in eDHFR, exchanges 65% of the cofactors. Values are for hDHFR only 
with unimolecular rates given in s-1 and bimolecular rates given in M-1·s-1. 
 
Interspecies DHFR homologues possess significant sequence differences. Indeed, it has been 
reported that a homology of 75% exists between human and chicken DHFR. This difference is notable 
when it comes to substrates affinity and mostly to inhibitor potential. Additionally, in the biopterin 
model, N5 and N8 seem to be of importance for orienting the molecule. An eDHFR model in complex 
with 6-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine shows a cofactor coplanar with biopterin but 
tilted by roughly 45 degrees137.  
1.3.5.2 Substrates and Inhibitors 
DHFR promotes the conversion of folate to FH2 and to a larger extend FH2 to FH4 in a NADPH-
dependent fashion (KM (FH2) = 2.7 ?M, KM (NADPH) = 4 ?M). FH4 is an essential component of the DNA 
synthesis pathway therefore its biosynthetic pathway is targeted for the development of antibiotics. The 
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enzyme, in the context of the BH4 metabolic network converts BH2 to BH4 (1-50% of the FH2 to FH4 
conversion rate depending on the species130). Here, focus is brought to structural and mechanistic 
information related to BH2. As said previously, DHFR being a target of predilection in the treatment of 
several pathologies, and particularly in cancer treatment and as anti-bacterial target, a vast amount of 
small molecule inhibitors have been developed138. Here, only the most potent and widely used tool 
compounds will be described. Very early in the description of the folate metabolism, it was discovered 
that 4-amino substituted folic acid derivatives were potent inhibitors. MTX and APT (Structure on Table 
3) were described as low pM range DHFR inhibitors and widely used as tool compounds and as 
treatment in oncology. Trimetoprim (TMP) is a potent drug against eDHFR as it binds 105 times stronger 
to bacterial than to mammalian DHFR. Several sulfa drugs such as sulfamethoxazole, sulfadiazine and 
sulfisoazole present inhibitory potential towards eDHFR. TMP is commonly used in combination with 
sulfamethoxazole as antibacterial agent due to their synergistic effect against folate metabolism133.  
1.3.6 Pterin-4?-carbinolamine dehydratase (PCD) 
1.3.6.1 History of the Discovery 
PCD was first observed as a contaminant during the purification of glucose dehydrogenase in the 50-
ies139, and later on found as a protein that stimulates PAH140. The enzyme was, two years later, correctly 
described as a homotetramer related to the pterin metabolism141,142. Its role as enzyme catalyzing the 
dehydration of 4HTP to qBH2 was established 10 years later by Lazarus et al.143. Later, PCD implication in 
the prevention of 7-substituted pterin non-enzymatic formation was established144. Curiously, it was 
realized that PCD had already been described as dimerization cofactor of hepatocyte nuclear factor ? 
(DCoH), possessing the same amino acid sequence145,146. The crystal structures of human and rat 
homologues were later solved, concluding the main description of PCD147. 
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Fig 11 Structure and catalytic mechanism of PCD. (A) Structure of the homotetramer. Helices responsible for 
the tetramerization are shown in dark. BH2 is shown as a blue “ball and stick” model. (B) Zoom on the active site and 
highlight of important amino acids. (C) Catalytic mechanism of the conversion of 4HTP to qBH2. Pdb reference : 1DCP 
 
1.3.6.2 Structure and Mechanism 
PCD is a 48 kDa homotetramer of D2 symmetry, composed of 103 amino acids per subunit being part 
of the open-faced ?-? sandwich structure family (Fig 11 A). The global enzyme arrangement can be 
described as a dimer of dimer. In each subunit, all the helices are aligned on one side in parallel with the 
anti-parallel ?-sheet structure. By sharing an ?-helix, each monomer contributes to the tetramer stability 
by forming a four helix bundle at the center. The enzyme possesses in total 4 actives sites for 4HTP to 
bind with no apparent residues shared between subunits to perform the catalytic activity147b. Only a BH2 
bound structure of PCD was crystalized as basis for determination of the different residues involvement 
in 4HTP dehydration. It is expected that Ser78, Glu61, His63, His80N and Asp81N anchor 4HTP in the 
active pocket via both hydrogen bonding and charge stabilization while His62 is believed to orient the 
cofactor upon binding (Fig 11 B). The dehydration processes through general acid/base catalysis with the 
first step being His63 mediated deprotonation from N8 (Fig 11 C). The formed anionic oxygen is 
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consecutively stabilized by His80N and Asp81N facilitating the 4a-hydroxyl lability. The latter is 
eliminated via an acid/base exchange mediated by either His62, His80 or water. Finally, as the amide 
reforms, qBH2 is liberated. The uncatalyzed reaction has been reported to be roughly 2000 folds slower. 
1.4 Biological Relevance of Pterins 
1.4.1 Amino Acid Hydroxylases 
The three hydroxylases (PAH, TYH and TPH) are part of the small family of monooxygenases all 
catalytically proceeding in a BH4 and molecular oxygen dependent fashion. Structurally, crystal structure 
studies revealed that the enzymes possess an N-terminal regulatory domain, a central catalytic domain 
and a C-terminal oligomerization domain (Fig 12, A). Very similar catalytic domains (52% to 60% residue 
homology), all specific towards BH4, bind in their active site a molecular divalent iron via two His and a 
Glu. Being homotetrameric, they possess a C-terminal region stabilizing the protein complex via a long ?-
helix (~40 residue, D2 symmetry). Finally, the N-terminal regulatory domains, composed of 100 to 160 
residues, possess a very low level of identity ( ~14 % )148 and is structured as an ACT domain (?????? 
topology). The three enzymes possess to some extend a way to regulate their activity either by post-
translational modification or allosteric binding. PAH is the only enzyme in this family shown to possess a 
homotropic ligand149. As the catalytic domain within the three enzymes is conserved, it is generally 
accepted that the hydroxylation mechanism is similar. The reaction can be described as a two-step 
process with (i) the formation of the hydroxylating intermediate, involving BH4, and (ii) the oxygen 
transfer to the substrate148. As seen on the mechanistic scheme described in Fig 12C the reaction yields 
4HTP. Due to the hydroxylases similarity only the crystal structure of PAH will be presented and 
described. 
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Fig 12 Structure and catalytic mechanism of PAH. (A) Top view of PAH. Each subunit is marked by a color and its 
subdomains by a shade of it. (B) Side view of PAH. Regulatory domains are at the extreme top and bottoms while the 
tetramerisation domain is in the center. The catalytic domain resides in the middle. (C) Catalytic mechanism for the conversion 
of Phe to Tyr. Pdb reference :5FGJ 
1.4.1.1 Phenylalanine Hydroxylase 
PAH catalyzes the conversion of phenylalanine to tyrosine in a BH4-dependent fashion. In order 
to avoid accumulation of phenylalanine but to leave it sufficient for protein synthesis, the enzyme 
activity must be tightly controlled. PAH is composed of an N-terminal 117 residues long regulatory 
domain. A 33 amino acid long flexible peptide spans over the active pocket acting, in the inactivated 
state, as a steric blocker for substrate binding150. The Phe driven enzyme activation mechanism is still 
debated nowadays. Two main mechanisms have been described, proposing (i) a large regulatory rotation 
and dimerization151 and (ii) local change driven by Phe binding at the active or N-term adjacent site152. 
Furthermore, the geometry of the regulatory domain (ACT domain) is similar to the PCD subunit 
geometry. These geometries are known to be dimeric to tetrameric in essence, emphasizing on enzyme 
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activation by dimerization. A recent report presented an activated PAH crystal structure in which an 
allosteric binding pocket, at two regulatory-domain interfaces, exists for two Phe to bind153. A large 
conformational twist liberates the active site in order for the reaction to take place. Additionally, BH4 
also acts as allosteric inhibitor presenting chaperone like characteristics. The allosteric substrate binding 
seems to induce a conformational change that keeps the enzyme in a low activity and low Phe affinity 
state154. Another mode of activation, involving phosphorylation of Ser16 was reported. This post-
translational modification disrupts the binding of the N-termini peptide inside the catalytic binding 
pocket and facilitates the enzyme activation. Close to the binding site is a disordered region containing 
Tyr138, a residue which is believed to act as hinge for water bridging BH4 potentially acting as regulator. 
This feature is not detailed in the presented crystal structure. Mechanistically, sequential binding in the 
catalytic pocket of PAH has been reported. BH4 binds first (Kd = 65 ?M) followed by Phe (Kd = 130 
?M)155. Interestingly, BH4 seems to have a 200 folds higher affinity than BH2. PAH can either be 
allosterically inhibited by BH4 or activated by Phe. Once activated, the enzyme can efficiently perform its 
catalytic task (KM = 15 ?M). The last 43 residues compose the C-terminal homotetramerization domain.  
1.4.1.2 Tyrosine Hydroxylase 
TYH catalyzes the formation of 3,4-dihydroxyphenylalanine via BH4-mediated hydroxylation of Tyr. 
3,4-dihydroxyphenylalanine is the precursor of the catecholamines dopamine, norepinephrine and 
epinephrine. As to now, no full TYH crystal structure has been reported. All models are based on 
computationally assembled truncated versions or NMR studies. Similarly to PAH, the regulatory domain 
possesses a disordered N-terminal peptide (AA 1-71) and a structured ACT domain C-terminal section 
(AA 72-159)156. The unfolded peptide is believed, also in the case of TYH, to hinder substrate binding by 
covering the active site. In solution, the regulatory domain is a homodimer which, adversely to PAH, does 
not appear to bear an allosteric binding site. Comparatively, the binding mode in the dimerization of 
both activated PAH and TYH regulatory domain is similar. Furthermore, TYH is activated by Phe and by 
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phosphorylation of the Ser19, Ser31 and Ser40 residues all located on the disordered N-terminal tail157. 
Additionally, catecholamines are known to inhibit the enzyme by competing with BH4158. Ser 
phosphorylation apparently decreases the inhibition by catecholamines159. The catalytic domain is 
composed of residue 160-456 and complexes its iron via His331, His36 and Glu376160. Interestingly, there 
seems to be no flexible loop, comparable to PAH Tyr 138, present in TYH. Finally, the long ?-helical C-
terminal tetramerization domain spans over the last 42 residues.  
1.4.1.3 Tryptophan Hydroxylase 
Two isoforms, TPH1 and TPH2, exist in mammalian multicellular organism with respectively mostly 
peripheral and central nervous system distribution161. TPH catalyzes the rate limiting formation of 5-
hydroxytryptophan, the precursor of serotonin (5-hydroxytryptamine, 5-HT) via BH4-dependent 
hydroxylation of Trp162. TPH is believed to be a main actor in occurrences of major depressive disorders. 
Structurally, the two TPH possess 71% of sequence identity mostly differing in their N-term region. 
Several Ser can be phosphorylated but no obvious consequence has been observed for all of these 
locations163. In TPH2 activation by Ser19 phosphorylation, a residue not conserved in TPH1, was 
reported. 14-3-3 protein family has been shown to bind and structure phosphorylated TRP164. This 
protein-protein interaction is still studied nowadays. Due to its relatively low in-vitro instability, only TPH 
catalytic domain was crystalized165. Therefore, there is no structural basis to study in detail the 
regulatory and oligomerization domain mechanisms. TPH substrates have been reported to bind in the 
active site in a random fashion before undergoing hydroxylation. TPH is regulated in-vivo by serotonin 
and 5-HT via competitive inhibition.  
1.4.2 Nitric Oxide Synthesis 
Due to its importance in biological processes, nitric oxide (NO) is nowadays a hot topic generating in 
2016 more than 1500 publications containing “nitric oxide” in their titles. Here, only mechanical and 
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structural information on NO synthases (NOS) and effects resulting from BH4 deficiencies or linked to 
BH4 are discussed. Physiologically, NO has several crucial functional roles166. NO is a polyvalent molecule, 
in neurons it acts as neurotransmitter, in activated macrophages it is generated as antimicrobial agent, in 
endothelial cells it regulates apoptosis while it is also a vasodilator and inhibitor of platelet aggregation.  
NO is synthetized by NOS by abstraction of a nitroso group from the Arg guanidino moiety to yield L-
citrulline167. Three forms of NOS exist: endothelial NOS (eNOS), neuronal NOS (nNOS) and induced NOS 
(iNOS) all structurally similar (50-60% homology) and BH4 dependent168. eNOS and iNOS supply the basal 
NO in a Ca2+/calmodulin(CaM) modulated fashion. iNOS, as its name implies, is induced in case of 
inflammatory immune response and is Ca2+, but not CaM, independent169,170,171. Mechanistically, NOS is 
dependent on NADPH, flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), iron heme b, 
molecular oxygen and BH4 substrates. BH4 is not consumed during NO synthesis and acts as a structural 
cofactor essential in forming active dimeric NOS. Bound in proximity to the heme ring, BH4 is in a 
cationic state and gives a proton and an electron to the heme iron-O2 complex. The heme bound Fe
2+ 
and BH4 are regenerated by electrons supplied by NADPH via a cascade involving FAD and FMN. 
Furthermore, the dimer and BH4 reduced state is maintained by a tetrahedrally coordinated Zn ion. 
Structurally, NOSs are composed of two domains: an oxygenase and a reductase domain. The oxygenase 
domain, located at the N-terminus, possesses a CaM-recognition site and binding sites for BH4, heme 
and Arg. The C-terminal reductase domain contains the FAD, DMN and NADPH binding sites. Several 
structural features differ between each NOS isoforms such as the size of their domains, loop organization 
between the different binding pockets and a PDZ recognition domain only found in iNOS. The PDZ 
domain, a protein interaction motif, is believed to be binding to glutamate or melatonin receptors172. 
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Fig 13 Global structural features of NOSs. (A) NOSs are composed of two main domains: the 
reductase (blue) and oxygenase (green) domains. Electrons are carried from the oxidation of NADPH 
through FAD and FMN to the Heme b. Arginine binds into the oxygenase domain of the BH4 stabilized 
NOS to be converted to citrulline and release NO. A CaM binding pocket exists in between the two main 
domains regulating the structure and electron flow. (B) Schematic description of NOSs individual 
features. The two main domains are structurally similar but vary in size. Loop organization of the FMN 
binding pocket. nNOS is the only synthase possessing a PDZ domain for protein interaction. 
 
BH4 and BH2 have both been shown to bind with and equal and high affinity of Kd = 80 nM to all 
forms of NOS173. BH4 and BH2 bound NOS have been respectively termed “coupled” and “uncoupled” 
NOS catalyzing different reactions. In the coupled form, NOS promotes the synthesis of NO while the 
BH2-bound enzyme will promote the formation of superoxide. As no electron can be shared with heme, 
the oxygenase domain becomes inactivated. NO and superoxide can rapidly combine to form 
peroxynitrite, a reactive nitrogen compound. At physiological levels, ROSs such as peroxides, free oxygen 
radicals and oxygen ions have a role of signaling molecules and regulators of several cellular processes174. 
Pathological conditions, in the case of BH4 deficiencies, arise when the ratio of BH4 over BH2 becomes 
close to unity. It has been shown that the relative amount of BH4 towards BH2 and not the absolute BH4 
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amount is the determining factor in NOS uncoupling173. Consequent superoxide anion release is often 
followed by oxidative stress mostly due to the formation of peroxynitrite, the molecule formed via NO 
and superoxide reaction. The latest has a propensity to oxidize BH4, classically leading to further NOS 
uncoupling which in turn worsens the oxidative stress condition. Nitrosative stress further increases as 
peroxynitrite triggers the release of zinc from eNOS175. Additionally, peroxynitrite can cause S-
nitrosylation of proteins, lipids and DNA. Generally, cardiovascular complications and atherosclerosis 
arise as a result of this oxidative stress. Evidence of the implication of iNOS generated peroxynitrite in 
Alzheimer’s disease has been demonstrated176.  
It was shown that NOS activity increases in cases of immune response177. As a consequence to 
inflammatory stimulation, GCH1 upregulation directly impacts levels of BH4. Increase in iNOS activity 
seems to be linked specifically to BH4 levels. In endothelial cells, iNOS mRNA was decreased upon 
stimulation but a six fold increase in NO production was measured indicating that BH4 concentration is 
the determining factor in this process78. Yet, this model is hard to confirm on humans178, shows to be 
species dependent, and culture method and state of the cells appears to have an impact as well179.  
1.4.3 Phenylketonuria 
Classical PKU results from an inborn genetic mutation in the phenylalanine hydroxylase codon. 
Phenotypical consequences range from mild (120 – 600 ?mol Phe/L blood) to pronounced 
hyperphenylalaninaemia (HPA, > 1200 ?mol Phe/L blood)180. Statistically, PKU prevalence is of 1 over 
10000 live birth in Europe181. Usually, patients with mild PKU are on a strict phenylalanine-restricted diet 
with a tolerance between 250 to 400 mg/day182 whereas in classic, severs, PKU the daily phenylalanine 
intake must not exceed 250 mg. Atypical PKU represents as little as 2% of the global PKU cases. These 
cases can be caused by mutations in enzymes responsible for BH4 biosynthesis or regeneration such as 
GCH1, PTPS, SPR, PCD and finally DHPR183. It has been reported that 29 mutations in the QDPR gene 
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(encoding for DHPR) are responsible for the enzyme’s partial or total loss of function. DHPR function 
deficiency leads generally, despite the phenylalanine-restricted diet, to crescent physical and mental 
impairment. These symptoms can be followed by basal ganglia calcification and death. A mechanism can 
explain such devastating syndromes: BH2, being an hydroxylase and NOS inhibitor, accumulates184 
leading to the decreased production of L-Dopa, 5-OH-tryptophan113,185. Another form of atypical PKU, 
detected by excretion of 7 substituted pterins, PAH inhibitors as well, is due to PCD deficiency. These 
chemical rearrangements are usually minimized by PCD144, 186.  
1.4.4 Dopamine-Responsive Dystonia 
Dopamine-responsive dystonia (DRD) also known as Segawa’s disease is a disorder induced by 
critically low doses of L-dopamine (L-DOPA). This phenotype is generally linked to autosomal dominant 
mutations of the gch1 gene in priority and infrequently the tyh and spr genes187. Traditionally, dystonia is 
observed at a young age with mild Parkinsonism. Occurrences of tyh and spr related cases of DRD often 
lead to more dramatic syndromes such as mental retardation, Parkinsonism and oculogyric crises. 
Generally, such atypical clinical syndromes fall in the DRD-plus category188. Newborns with DRD 
sometimes present HPA, detected at birth neonatal PKU screening. However, DRD in HPA-free patients is 
only detected later by classical symptoms. A biochemical marker is the significantly reduced levels of 
total biopterin and neopterin in the cerebro-spinal fluid189. SPR deficiency is believed to be the main 
factor in HPA-free DRD. Complete BH4 synthesis can be performed out of the CNS without SPR 
(discussed previously – SPR chapter). As DHFR is weakly expressed in the cerebrospinal fluid, BH2 
generated via the salvage pathway cannot be converted and accumulates, consequently inhibiting TYH 
and TPH113. Other reports indicate an increased vulnerability of nigrostriatal dopaminergic neurons 
towards BH4 deficiencies compared to liver cells. BH4 was shown to stimulate gene expression of TYH, 
therefore its low levels obstruct TYH enzyme activity190. As improvement in patient condition is usually 
obtained upon treatment with L-DOPA, DRD is not a neurodegenerative but a biochemical disorder.  
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1.4.5 Neuropathic Pain 
Neuropathic pain is usually associated with tissue and nerve injury and is often a chronic pathology. 
In opposition to classical inflammation, nerve injury is therapeutically hard to tackle. Classically, in 
healthy mammals, BH4 production from the de novo pathway is low and tightly regulated while recycling 
and salvage pathways maintain homeostasis191. Following nerve damage, BH4 levels have been reported 
to significantly increase in sensory neurons and macrophages192. The consequence of this cellular stress 
is an increase in transcription, translation and therefore activity of GCH1, usually the rate limiting 
enzyme in BH4 synthesis. It has been revealed, through patients with GCH1 genetic polymorphism, that 
decreased levels of BH4 reduced pain192. This was confirmed by inhibiting GCH1 with DAHP in rats with 
nerve injury and inflammation. Consequently, elaboration of SPR specific inhibitors for the development 
of analgesics was undertaken. A summary of those drugs can be found in the “SPR” chapter. Inhibition of 
SPR still allows production of BH4 to basal levels via the salvage pathway while GCH1 inhibition would 
reduce total BH4 amount on the long run. Treatment with the SPR-inhibitors SSZ or SPRi3 for extended 
periods of rats with nerve injury and inflammation, prevented and reversed hypersensitivity, providing 
evidence that SPR inhibition might have therapeutic utility193,115.  
Mechanistically, in the sensory neurons of a naïve reporter mice low levels of GCH1 are present. 
Following peripheral nerve injury and persisting after 7 days, gch1 transcription is increased proximal to 
the injury in all major sensory neuron classes as well as in macrophages. In both cells, significant BH4 
overproduction was measured. Injured mice were tested for chemical (capsaicin) as well as radiant and 
contact heat and showed that high level of BH4 affects the sensitivity of somatosensory neurons. It was 
shown that BH4 sensitizes TRPV1 channels via nitrosylation due to increased NO synthesis115. Increased 
pain manifestation such as allodynia and hyperalgesia is a direct consequence of these sensitized 
receptors. 
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1.4.6 Alkylglycerol Monooxygenase 
Alkylglycerol monooxygenase (AGMO), also known as glyceryl ether monooxygenase, is the enzyme 
responsible for the BH4-dependent hydroxylation of alkylglycerols. AGMO cleaves the ether bond of 
alkylglycerols ether phospholipids yielding, via an unstable hemiacetal, the resultant glycerol derivative 
and a fatty aldehyde (Fig 14A). Generally, saturated lipids from 14 to 22 carbons are processed by the 
enzyme194. These ether lipids can be found in the brain structure, the cataract and in the development of 
semen195. They are also believed to influence platelet-activating factor inflammation196. 6MPH4 was also 
shown to be a suitable substrate197.  
Being an integral membrane enzyme, no purification has been successful so far and therefore little 
structural insight is known. A bioinformatic model, partial bacterial and mammalian cell expression as 
well as mutagenesis allowed proposing a global structure and a putative binding site (Fig 14B). 
Furthermore, the enzyme lacks homology with any known BH4-dependent enzyme. Structurally AGMO 
appears to be composed of nine transmembrane helices covering roughly half of the enzyme sequence. 
A structural motif composed of eight His are reported to be crucial for catalysis198 indicating a di-iron 
center, classical in BH4 and O2 mediated hydroxylation, is involved in the catalytic process. Similarly to 
other BH4 binding proteins, anchoring of BH4 is performed via the Glu137 residue (KM =~ 33.5 ?M) 
located in proximity to the His motif199.  
Recently, a report highlighted the importance of BH4 in lipid homeostasis in a murine macrophage 
model200. AGMO was in the case of M1 (INF-? & LPS activated) and M2 (interleukin 4 activated) bone 
marrow macrophages respectively down and upregulated. No tangible explanation for this regulation 
has been proposed as for now. These regulations were shown to reverberate directly on the lipidome 
and beyond ether lipids.   
- 39 - 
 
A 
 
B 
 
Fig 14 AGMO catalytic mechanism and schematic structure. (A) AGMO promotes, in a BH4 dependent fashion, 
alkylglycerol cleavage yielding a fatty aldehyde and a glycerol derivative. (B) Schematic structure of AGMO. AGMO being 
transmembranar, no crystal structure exists.  
 
1.4.7 Vitiligo 
Vitiligo is a skin condition characterized by local depigmentation of the epidermis due to 
melanocytes loss of function201. Several combined mechanism such as genetic, immunologic and 
environmental factors, seem to generate melanocyte destruction202. The most accepted mechanism is 
based on an interplay between oxidative stress and autoimmune response203. 
Dermal accumulation of H2O2 to mM levels coupled with low catalase activity, decrease of 
antioxidant agents and increase in 6- and 7-biopterin concentration is believed to be a main cause of 
vitiligo generation204. As previously presented, accumulation of 7-isomers of biopterin has been linked to 
impairment of PCD. The low PCD activity is worsened as critical catalytic residues are oxidized in the 
presence of high H2O2 concentration
205. In patients with vitiligo, PCD activity was significantly lower than 
the other BH4 metabolic pathway enzymes206. In addition, isomerization of 4HTP is favored under the 
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presence of H2O2. These 7-pterin have been reported to be potent PAH competitive inhibitors (Ki in low 
?M range)205 directly being reflected by the PAH activity decrease and Phe concentration increase in 
patients207,208. This inhibition in turns favors the formation of H2O2. Consequently, Tyr depletion leads to 
a decrease in tyrosinase produced melanins. 
Furthermore, at such levels H2O2 deactivates catalase and oxidizes the tetrahydro form of pterin 
isomers. Moreover, H2O2 concentrations as high as 30 ?M have been shown to significantly decrease 
DHPR activities, diminishing BH4 recycling204. Accumulation of this oxidized pterin can be observed by 
skin fluorescence at 351 nm206. Additionally, high local H2O2 concentration leads to increased 
intracellular ROS by initiation of NOS driven oxidative stress. Prolonged and extensive oxidative stress 
leads to peroxinitrite and ROS driven protein aberration potentially serving as autoantigens leading to 
autoimmunity in parallel to cytokine induced apoptosis209.  
In retrospect, it appears that oxidative stress is the initiating event in the cascade leading to 
vitiligo210. Finally, it has been shown that substitution of the defective epidermal catalase leads to 
repigmentation of the skin206. 
1.5 In Vivo Pterin Quantification 
1.5.1 Chemical Oxidation 
Chemical oxidation has been widely used in the early studies of pterins biological relevance as it is a 
simple alternative for the indirect quantification of BH4 and BH2. The physical property of BH4 renders it 
non fluorescent while BH2 only has 4% of biopterin fluorescence and is therefore hardly detectable. 
Traditionally BH4, BH2 were chemically oxidized to be later detected by fluorescence211. In one hand, 
acidic oxidation in the presence of iodine transforms both BH4 and BH2 to biopterin212 (1 M HCl, 10 
mg/ml I2, 20 mg/ml KI, 1 h, RT). On the other hand, using basic conditions in the presence of iodine (1 M 
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NaOH, 10 mg/ml I2, 20 mg/ml KI, 30 min, RT) would transform, non-quantitatively, BH4 to pterin, a highly 
fluorescent molecule, while BH2 would oxidize to biopterin. This method was used in the study of small 
molecule inhibitors on SPR119 and quantification of pterins in living organisms and tissues. 
1.5.2 Electrochemical Detection 
Methods employing reverse phase HPLC separation followed by post-column electrochemical 
oxidation and detection coupled with fluorescence were developed following the chemical oxidation 
method213,214. This application relies on the capacity of coulometric electrochemical detectors to 
quantitatively oxidize compounds flowing through the high surface-area porous working electrode215. 
Advantage of such a method is sensitivity and linearity over pico- to micromolar concentrations. 
Furthermore, the additional dimension brought by the different oxidation potentials applied post-
column allows for differentiation and quantification of co-eluting molecules. Experimentally speaking 
this method is robust and apparatus maintenance is limited to column cleaning from cellular debris.  
1.5.3 Liquid Chromatography Mass Spectrometry 
The latest quantification methods rely on hydrophilic interaction liquid chromatography (HILIC) 
based separation216 followed by mass spectrometry quantification217,218,219. HILIC columns were 
developed to efficiently separate tens of closely related pterin compounds allowing one to draw the 
complete pteroidic metabolic landscape. Adequate separation by HILIC, coupled to the sensitivity of 
triple quadrupole modules is the state of the art. This method is however more expensive and requires 
dedicated instruments as the types of buffers and columns are not routinely used in chemical synthesis. 
1.6 Semi-Synthetic Sensors 
Sensing metabolite concentration and quantifying competitive enzymatic inhibition both in vivo 
and in vitro provides a large pool of information in the study of biological processes. Sensors based on 
fusion proteins and chemical linkers are able to achieve such performances. Several technologies are 
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combined together in order to build a functional and reliable sensor220: (i) genetically encoded scaffolds 
are built by the assembly of several protein sub-units, (ii) self-labeling proteins such as SNAP, CLIP or 
Halo are used as said sub-units in order to shape the sensor’s functionality. (iii) Small molecules, 
synthetic probes and tag substrates are assembled by organic synthesis. (iv) Those sensors most often 
rely on the Förster Resonance Energy Transfer (FRET) and Bioluminescence Resonance Energy Transfer 
(BRET) obtained by the rational design of the sensor scaffold. Fig 15,A/B pictures one of the most 
common designs of a SNIFIT (SNAP-tag based Indicator protein with a Fluorescent Intramolecular 
Tether)221,222. The scaffold is assembled part by part in order to yield the functional sensor. The sensor is 
closed when no competitive substrate is present thus allowing the donor and acceptor to be in close 
proximity to each other, yielding high FRET efficiencies. In the presence of a free analyte, the tethered 
substrate will be displaced therefore lowering the FRET interaction between the donor and acceptor 
which can be monitored using a spectrofluorometer. In the case of a BRET sensor223, a luciferase replaces 
the genetically encoded fluorophore in the sensor. In the presence of additional luciferin the 
bioluminescence emitted by the luciferase is bright enough to be captured on a common camera. 
Several important features have to be noted: The proline 30 (P30) linker, expected to form a rigid helix, 
is used to increase the distance between the FRET donor and acceptor therefore strongly decreasing the 
FRET when the internal substrate is unbound. The FRET efficiency difference between the open and the 
closed sensor is therefore expected to be strongly increased. However, in the case where a more flexible 
linker is required, the P30 linker can, by insertion of several glycine-glycine-serine (GGS) units, adopt 
different conformations. Another important factor in the design of sensors is the choice of an efficient 
FRET pair. Usually tetramethylrhodamine (TMR) and silicon rhodamine (SiR) are used for the large 
spectral overlap and the red-shifted signals they emit (570 nm and 650 nm, respectively). Furthermore, 
the proteins can be modified to accommodate an unnatural amino-acid224 which can later be conjugated 
to a synthetic dye in order to replace a bulky self-labeling protein225(Fig 15C).  
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Fig 15 Typical Snifit scaffold. The base structure is genetically assembled and expressed. The 
tags and the fluorophores are chemically synthetized and self-assembled. The sensor is closed (A) 
and high FRET is emitted when no competitive substrate (blue dot) is present. The competitive 
substrate can displace the tethered ligand and open the sensor (B) and therefore low FRET is 
emitted. (C) Scaffolds bearing an unnatural amino acid can be bound to a synthetic dye in order to 
replace a self-labeling protein. 
 
The main advantage of such sensors in screening campaigns is the ratiometric nature of their 
readout. This generally translates to better reproducibility of the results as concentration of the sensor in 
solution doesn’t impact on quantification of a molecule towards the protein of interest. The quality of 
the readout is dependent of the distance and orientation between the two fluorophores. Indeed, when 
in close proximity the FRET efficiency will be higher. Furthermore, optimal FRET occurs when the 
excitation dipole of the donor dye is parallel to the absorbance dipole of the acceptor dye. Finally the 
spectral overlap between the donor and acceptor dyes as well as their spectral overlap lay an important 
role with respect to the amount of transferred energy226.  
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Chapter 2. Results 
2.1 A Sensor for DHPR Inhibitors 
A semi-synthetic FRET based sensor was developed in order to screen for competitive DHPR 
inhibitors. The theoretical design principle is introduced in the following section followed by the sensor 
creation.  
2.1.1 Sensor Development Strategy  
The final sensor design was obtained through a step-by-step approach consisting of testing each 
parameter before obtaining a robust sensor that could be used in a large drug screen. As seen in Fig 16 
the first step (Fig 16A) is to test known inhibitors in an enzymatic assay (Fig 16F). Generally, inhibitors 
possessing moieties that are easily derivatized and that possess the strongest binding potentials are 
preferred. Further on, the effect of chemical modification on their inhibition potential is investigated. 
This allows for quantification of a compound’s loss of potential and directs the development of the 
Fig 16 Scheme for the development of semisynthetic FRET sensors. (A) The enzyme of interest, here DHPR, is first studied 
in an enzymatic assay. (F) Different known inhibitors are tested via the enzymatic assay. The compounds are derivatized and 
tested to ensure their conserved potency. A dye (TMR) and a self-labeling tag (BG) are then added to form a complete linker. (B) 
The enzyme is modified by fusing it to a self-labeling protein to form the minimal scaffold. Its catalytic activity is assessed to 
confirm its integrity. The minimal scaffold in labeled and tested for fluorescent polarization (G) and enzymatic assay. The 
capacity of the tethered inhibitor for binding and unbinding is assessed via this experiment. (C) A poly-proline spacer is added to 
increase the distance between the protein of interest and the self-labeling protein to form the spaced scaffold. The spaced 
scaffold binding ability is tested again via enzymatic assay and fluorescent polarization. (D) A second self-labeling enzyme is 
fused and linked to a second dye (SiR) to form the FRET sensor. (H) FRET is recorded in the bound (closed) and unbound 
(opened) situation. (E) The first FRET sensor is optimized using various methods 
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linkers further. Indeed, the latest step is to incorporate a dye such as TMR, a spacer (polyethylene glycol) 
and a self-labeling tag such as BG.  
DHPR is fused to the self-labeling protein SNAP on either C or N-termini and tested enzymatically (Fig 
16B). The catalytic ability of the construct, here denominated minimal scaffold, is assessed via the 
enzymatic assay. This experiment ensures complete preservation of DHPR functionality. These small 
fusion proteins are then labeled with a linker bearing a tethered inhibitor and a fluorophore. The highest 
possible local concentration of inhibitor in fusion proteins is obtained this way. These scaffolds are 
tested enzymatically in order to evaluate the intramolecular inhibition from the tethered drug. Through 
this assay it is possible to estimate the local concentration of tethered inhibitor.  
Binding and displacement of the tethered inhibitor from the active site is then investigated by 
fluorescence polarization (Fig 16G). Free inhibitor is added, in solution, to a labeled minimal scaffold, 
displacing its tethered counterpart allowing the fluorophore to regain mobility. The assay allows to test 
opening (unbinding of the tethered inhibitor) and closing (binding of the inhibitor) of the minimal 
scaffold. The enzymatic assay and FP steps can be repeated after the insertion of a P30 spacer between 
the protein of interest and SNAP. (Fig 16C) The objective is to verify that binding still occurs in a spaced 
scaffold, a system were the binding site is further from the SNAP attachment point.  
Finally, a Halo self-labeling protein is added in order to accommodate the FRET acceptor dye SiR. (Fig 
16D) The efficiency of the two dyes to perform FRET is assayed (Fig 16H). Ratio of signal of the acceptor 
dye over the donor dye is measured in the closed and open sensor conformation. The first iteration of 
the FRET sensor can be optimized using various methods such as scaffold stiffening, circular 
permutation, and insertion of unnatural amino acids serving as handle for fluorophore coupling. 
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Fig 17 DHPR assay and KM determination. (A) Scheme of the assay. FICC is rapidly reduced by BH4 to FOCC to yield 
qBH2. qBH2 is then reduced enzymatically by DHPR. (B) Results of the DHPR enzymatic assay. 6MPH4 is used as substrate. 
As controls independent wells lacking DHPR and containing only FOCC are assayed. (C) KM constant measurement. Each 
point is the average of 3 measurement ± SD. 
 
2.1.2 DHPR Assay 
The assay was run on human DHPR as described in material and methods. Briefly, 
ferricytochrome-c (FICC) and BH4 (in the experimental case 6MPH4) quickly react to form 
ferrocytochrome-c (FOCC) and qBH2 (in the experimental case 6MqBH2). qBH2 is then reduced by DHPR 
to complete the cycle (Fig 17A). FICC and FOCC were also added to separated wells to determine the 
reaction starting and ending points. Upon total conversion of FICC, by the enzymatic reaction, the 
plateau reached the FOCC signal level (Fig 17B). Conditions without DHPR showed that non-enzymatic 
reduction of FICC could take place as previously reported. This was due to the relatively slow non-
enzymatic conversion of qBH2 to BH4 by NADH. However the enzymatic reaction rate was roughly 70 
times faster and can be afterwards corrected to measure the exact enzymatic rate. Influence of DMSO 
on the assay was tested and no noticeable change in the reaction rate could be observed with up to 10% 
V/V DMSO. Nevertheless, care was taken to keep DMSO concentrations constant over the whole assay 
- 48 - 
 
and set to a maximum of 1%. The KM was measured by titrating 6MPH4 at five concentrations. Upon 
fitting with a Hill function, the estimated KM was found to be 0.55 ?M (Fig 17,C). This value was in 
accordance with reported values of 0.15 to 18 ?M. This difference might be due to the choice of 
synthetic cofactor 6MBH4 whereas the reported values were measured with either BH4 or 6,7MPH4. 
Furthermore our assay used 50?M NADH instead of 100?M used in the literature. Inhibition of the 
enzyme was performed as a control with APT and MTX (Fig 18). The reported higher affinity of APT for 
DHPR in comparison to MTX was verified. Ki of 31 and 102 ?M for APT and MTX respectively were found. 
 
Fig 18 Inhibition assay of DHPR with APT and MTX. Inhibition potential 
of APT (orange) and MTX (was) against DHPR. A titration was made starting 
from 1mM. Each point is the average of 3 measurement ± SD. 
 
Through this assay it was seen that DHPR is a relatively robust enzyme, stable at room 
temperature and unaffected by low concentrations of DMSO. Values obtained for the enzyme 
characterization were consistent with the values reported in literature. The best known inhibitor was 
assayed in an inhibition assay and the Ki was measured. Ki for APT was similar to what has been reported 
(Ki(repo) = 20?M, Ki(found) = 31?M) while Ki for MTX diverges by a factor of three (Ki(repo) = 38?M, Ki(found) = 
102?M).  
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However, it was impossible to increase the inhibitors concentrations to obtain complete enzyme 
inhibition due to their insolubility at higher concentrations. 
The used inhibitors possess two carboxylic acid moieties that can later be used for derivatization 
and linker design. The affinity of these compounds is, in comparison to those that were used before in 
literature for the design of sensors, similar to weaker. DHFR and SPR based sensors have been using nM 
range tethered inhibitors while a sensor for glutamate has been reported with similar tethered substrate 
affinity223,222. 
2.1.3 Drug Derivatization and Linker Synthesis 
In order to create a functional linker for the complete sensor, primary aminohexyl conjugates of 
MTX and APT were synthetized (Fig 19, A). These drugs possess accessible carboxylic acid moieties for 
straightforward amide bond formation. Both derivatized drugs were tested in order to assess the loss of 
inhibitory potential towards DHPR. The enzymatic assay was run with 250 ?M of APT, APTC6NH2, MTX 
and MTXC10NH2. A control containing no drug is run in parallel (Fig 20). The observed reaction rates for 
DHPR only, MTX and ATP are similar to what was observed in previous enzymatic assays. It is observed 
 
Fig 19 Inhibitor derivatives and fluorescent linkers. (A) Derivatized inhibitors are modified on one of their carboxylic acid 
moiety. (B) Small fluorescent SNAP binders based on the TMR dye are synthetized and used as controls for unspecific inhibition 
(C) Full linkers of various size were made based on APT. (D) SiR-Halo is used to couple SiR to the Halo-tag self-labeling protein 
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that APT and APTC6NH2 both decrease the reaction rate to a larger extend compared to MTX and 
MTXC10NH2. A similar affinity for both MTXC10NH2 and APTC6NH2 towards their respective original 
compound was observed. The retained affinity seemed suitable for sensor construction. Since APTC6NH2 
was shown to be a more potent inhibitor than MTXC10NH2 all further synthesis were performed with this 
compound. Three linkers L2, L5 and L11 (Fig 19C) of various lengths were synthetized. All linkers contain 
a BG group for labeling of SNAP-tag, a TMR fluorescent dye as emitting FRET partner and ethylene glycol 
spacers of various sizes. Control linkers L2C, L5C and L11C (Fig 19B) lacking the tethered APT were 
synthetized, to assess unspecific interactions. 
 
Fig 20 Inhibition assay of DHPR with derivatives of APT and MTX. DHPR rate of reaction was compared with 250 uM of 
unmodified and derivatized APT and MTX. Each point is the average of 3 measurement ± SD. 
 
Binding of the tethered drug to DHPR, once attached to SNAP, is a requirement in order to 
obtain a functional FRET sensor. As a mean to study this interaction the fusions SNAP-DHPR and DHPR-
SNAP were expressed as so-called minimal-scaffolds. Labeled and unlabeled minimal scaffolds were 
assayed in standard enzymatic conditions and rates were compared to native DHPR. As seen on Fig 21 
the V0 rates for DHPR and unlabeled SNAP-DHPR are comparable. DHPR-SNAP showed a slightly 
increased rate versus DHPR rate, but the difference might be due to the errors in the estimation of 
protein extinction coefficient. Rate of labeled versus unlabeled construct are roughly two times smaller 
in the case of SNAP-DHPR. The local inhibition due to the presence of tethered APT would correspond to 
an effective concentration of approximately 1 mM APT or 4 mM APTC6NH2. The change of reaction rate 
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indicates a semi-closed conformation of the constructs. Theoretically, the system was approximated as a 
set of two spheres in which a ligand is tethered to one of them. Using PyMOL, the linker length was 
estimated to be approximately 57 Å. Taking the linker length as a sphere radius giving one molecule in 
the sphere allowed us to estimate an effective molarity of ~10 mM. Using a more sophisticated random-
coil polymer model to measure intramolecular molarity, a concentration of 5 to 15 mM (depending on 
the linker size) should be expected227. These predictions are in close correspondence to the measured 
values presented above. 
 
Fig 21 Comparison between DHPR, labeled and unlabeled minimal scaffolds. SNAP-
DHPR and DHPR-SNAP were tested, labeled and unlabeled, in an enzymatic assay. The rates 
were compared to wild type DHPR. Each point is the average of 3 measurement ± SD. 
 
It was observed that no loss of inhibition potential took place upon drug derivatization, yielding 
suitable precursors for the synthesis of complete linkers. Additionally fusing SNAP to both DHPR N and C 
termini did not affect the enzyme reaction rate. Furthermore, in the case of the tethered inhibitor, due 
to the high local concentration, binding could be observed via the enzymatic assay. The rate of reaction 
remained fairly high indicating partial binding of the tethered inhibitor to the DHPR fusion protein. In 
order to consolidate these observations the system was tested in fluorescence polarization (FP) assay.  
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2.1.4 Anisotropy Study of the Binding 
DHPR requires first binding of NADH in order to bind its second cofactor qBH2. This could not be 
verified in the enzymatic assay, but could instead be tested with the FP assay. SNAP-DHPR and DHPR-
SNAP were labeled with L2, L2C, L5, L5C, L11 and L11C and polarization was measured at different NADH 
concentration. No polarization change could be observed in any conditions. However, as seen in Fig 22, a 
change in total intensity could be observed. This change can be translated as an environmental effect on 
the dye. It can be observed that this change of intensity occurs for all linkers at roughly the same 
concentration with similar amplitude. All the control linkers were tested and showed a comparable 
intensity and linearity over the whole concentration range. Hence, for the sake of clarity only L11C is 
shown. The observed low nM IC50 corresponds to a mix between sensor titration and linker binding. 
Indeed, in the assay the sensor concentration was 50 nM. The affinity of DHPR for NADH being Kd = 20 
nM it cannot be concluded that the observed change are strictly due to NADH binding. It can be 
observed that the signal reaches plateau at 1 ?M NADH indicating saturation of the system closed state.  
In order to confirm that the observed intensity change was due to binding of the tethered drug 
to the active site, displacement of the ligand was attempted by titrating APT at a fixed NADH 
concentration. Both constructs were labeled with L5 and L5C, NADH was kept at 50 ?M and APT was 
  
Fig 22 Fluorescence intensity assay of labeled minimal constructs. SNAP-DHPR (left) and DHPR-SNAP (right) were labeled 
with the linkers (L2,L5 & L11) and the control linkers (L2C, L5C & L11C) and titrated with various NADH concentrations. No 
signal in anisotropy could be observed but a total intensity change could. For the controls only L11C is shown for the sake of 
clarity.  
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titrated from mM to nM concentration. As seen on Fig 23, there is a clear unspecific effect from APT on 
the system. It was observed that the effect takes place close to 1 mM. It cannot be excluded that the 
drug at this range of concentration is not totally dissolved and therefore might influence the system. 
However, the decrease in intensity observed for SNAP-DHPR starts in the ?M range, significantly before 
the drop due to APT. If the intensities are normalized over the L5C signal a dose response curve can be 
fitted. A smaller intensity change is observed for DHPR-SNAP in comparison to SNAP-DHPR. Furthermore, 
the EC50 for DHPR-SNAP is at high ?M concentrations. Both the relatively weak intensity change and the 
high EC50 values point towards a less favorable protein conformation for the tethered drug to bind in 
the case of DHPR-SNAP. In order to investigate the implication of DHPR in these unspecific effects L5 and 
L5C were attached to a SNAP-CLIP construct. An APT titration was performed and similar effects could be 
observed on the high ?M intensity decrease. This indicates a probable interaction of the drug with either 
the dye or SNAP.  
  
Fig 23 Fluorescence polarization, tethered ligand unbinding by APT. SNAP-DHPR and DHPR-SNAP were labeled with L5 and 
L5C. APT was titrated at a fixed NADH concentration in order to open the minimal constructs. Significant unspecific effects were 
observed on the control (left) the signal was corrected for those (right).  
 
Through this FP experiment no anisotropy changes could be observed. However, upon 
measuring total fluorescent intensity a signal increase was seen when titrated with NADH. Such artifacts 
point towards an interaction of the dye with its environment, most probably with DHPR upon binding. 
Indeed, the relatively short spacer (12 atoms) used between TMR and APT could force the dye to enter in 
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contact with residues close to the active site. The ability of the system to close in the presence of NADH 
was confirmed but it was impossible to distinguish which of the three linkers was the most suitable. The 
slightly better signal change of DHPR-SNAP upon NADH titration suggests this protein fusion might be 
more appropriate. Furthermore, displacement of the bound tethered drug was attempted with APT. In 
light of the unspecific effects observed upon titration of APT, potentially due to and interaction with 
TMR, it cannot be certain that the tethered drug unbinds. The constructs geometries will be investigated 
in-silico in order to rationally drive the sensor development.  
2.1.5 In-Silico Modeling for Rational Sensor Design 
No DHPR crystal structures bound to a pterin cofactor or a drug is available. Therefore, an in-silico 
docking computational model was calculated in order to orient the sensor development. Autodock Vina, 
a well-established, fairly user-friendly and well documented docking algorithm was used for this 
purpose. Being popular, Vina has been used in a majority (32% over all other algorithms) of studies 
involving docking between 2010 and 2013228. The algorithm is known to be a robust tool when it comes 
to flexible ligand docking into macromolecular targets. Furthermore, Vina accepts threading, which 
diminishes computational hardware requirement allowing desktop computers to perform the 
calculations in a reasonable time229. The software requires a preparation of the protein (lock, described 
in material and methods) and molecule (key). The binding pocket location for the endogenous cofactor 
has been well described and was used to define the boundaries of a search box surrounding it. Both MTX 
and qBH2 were used as keys. As a result, qBH2 was docked in the active site with its pterin ring parallel 
to the Trp90 a position known to be favorable due to ?-? stacking (Fig 24A). The qBH2 N5 was oriented 
towards the NADH molecule with N5 at 4.5 Å from the nicotinamide ring C4. This distance is reasonable 
in order for the molecule to perform a hydride transfer. Hydride transfer studies reported 3.4 to 3.6 Å230 
reaction distance and as comparison sepiapterin C1’ ketone has been reported to be located at 3.2 Å 
from the nicotinamide C4 in the SPR crystal structure107. Furthermore, N5 is also in close proximity of 
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Tyr150 a residue involved as proton acceptor essential for the reaction. Finally, the qBH2 1,2-
dihydroxypropyl side chain is oriented above the NADH cofactor, towards the center of the enzyme. This 
orientation would support a fusion of DHPR on the C-termini as a linker would favorably close in such a 
conformation. In addition, Varughese et. al.35 reported in 1992 the first DHPR crystal structure as well as 
a model of qBH2 binding mode. Their model supports the performed simulation and highlights the 
critical enzymatic active site features described in the docking.  
MTX was docked with a general orientation comparable to qBH2 (Fig 24B). The side-chain was 
oriented towards NADH but the molecule was flipped upside-down, its N5 pointing towards the solvent. 
This change in vertical orientation could be due to the increased size and flexibility of the molecule. 
Indeed, qBH2 is a rather rigid molecule with only the 1,2-hydroxypropyl chain being flexible (2 rotating 
bonds). However, MTX has a larger side chain with 10 rotating bonds and a phenyl ring allowing, during 
docking, for more conformational freedom and interactions outside of the active site. It was speculated 
that the general horizontal orientation of MTX with its side-chain pointing towards the enzyme center, 
similar to qBH2, was correct. However, the vertical orientation predicted by the docking model was 
presumably erroneous. Furthermore, the distance from the termini to the active site is shorter in the C-
terminal case than the N-terminal one. Generally, fusion on the termini closer to the active site yields 
sensors with larger FRET ratio changes. In light of the structural clues gathered through the in-silico 
model and the literature, it was decided that the future DHPR fusions would be carried on the C-termini.  
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Fig 24 Models of qBH2 and MTX docking in DHPR. Front and side view of qBH2 (A) and MTX 
(both green) (B) docking. NADH is shown in red, and Trp90, a residue expected to be involved in ?-
? stacking with the pterin ring, is shown in blue. qBH2 orientation towards the active site is similar 
to previously reported simulated models. MTX was docked flipped with the N5 pointing towards 
the solvent.  
 
2.1.6 Scaffold Spacing 
The next objective was to obtain the best balance between the closing capacity and the FRET 
signal ratio change between closed and open sensor state. Inserting rigid amino acid patches (poly-
proline) between DHPR and SNAP potentially increases the inter-fluorophore distance in the open 
sensor. In precedent published sensors, this strongly increased the signal ratio change between the open 
and closed sensor state231. It has been reported that a chain of 30 prolines (P30) strongly increased the 
maximal ratio change without significantly impacting the local concentration. 
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Fig 25 Enzymatic assay with DHPR-p30-SNAP. The construct 
was labeled with the linkers L2, L5, L11 and L11C and the rates of 
reaction were compared to the unlabeled one. Each point is the 
average of 3 measurement ± SD. 
 
To evaluate the effect of the insertions of a P30 linker the DHPR-P30-SNAP construct was 
expressed. The enzymatic assay was performed on the L2, L5, L11, and L11C labeled construct compared 
with the unlabeled one. The enzymatic rates of constructs labeled with a linker bearing a tethered drug 
were significantly reduced (50%) in comparison to the control (Fig 25). This was a strong indication that 
DHPR in the construct is bound to the tethered drug. Furthermore, the difference in conversion rate 
between L11C and the unlabeled construct can be explained by the fact that the labeled sensor 
concentration was measured by TMR absorbance while the unlabeled construct concentration was 
measured with its protein extinction coefficient. This could have induced significant errors in the 
concentrations even though the labeling efficiency was expected to be quantitative. In addition, no 
difference in the reaction rate for the different linkers could be observed even though theoretically L2 
should be too short. The separation due to P30 was estimated to be between 60 and 90 Å232 (without 
counting the SNAP and DHPR enzyme increasing the distance) while the L5 linker length was estimated 
as 57 Å and L2 was smaller. However, L11 with an estimated length of 77Å which would allow the 
tethered APT to reach into DHPR binding pocket should be the only linker presenting inhibitory affinity. 
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From this experiment it could be concluded that insertion of P30 was not deleterious to the 
tethered drug binding. Furthermore, it appears important to consider the linker and constructs size 
approximations carefully. Indeed, considering the system as rigid could be erroneous as it could actually 
be in a much more packed conformation allowing even short linkers to access DHPR binding pocket. 
DHPR-P30-SNAP was not tested in FP assay as most of the relevant information was already gathered 
with the minimal constructs and the current enzymatic assay. The sensor development was pursued 
further with the incorporation of the Halo-tag (noted only Halo in the description of fusion proteins) self-
labeling protein necessary for the incorporation of the SiR acceptor dye.  
2.1.7 First Sensor Iteration 
The DHPR-Halo-p30-SNAP fusion protein was expressed and purified. This construct possessed a 
Halo self-labeling protein able to selectively react with chloroalkanes. SiR was selected as the FRET 
acceptor in this system since the TMR-SiR FRET couple has good spectral overlap for FRET. The molecule 
Sir-Halo was used in all further constructs to label the Halo-tag protein. The sensor was labeled on SNAP 
with L2, L5, L11 and L11C and SiR-Halo and was titrated with NADH and NAD+. As seen in Fig 26 the signal 
at 665nm (from here referred as the SiR signal) increases upon titration with NADH indicating that the 
sensor is closing and that TMR comes in closer proximity to SiR. Furthermore, it was observed that the 
A 
 
B 
 
Fig 26 Labeled DHPR-Halo-P30-SNAP titration with NADH. The sensor was labeled with the linkers, L11C and Sir-Halo and 
was titrated with NADH. The SiR signal increases upon NADH concentration increase (left, L11). The 3 linkers give rise to 
different ratio changes (right)  
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ratio change was smaller with L2 compared to L5 and L11 which show larger ratio changes (Fig 26B). It 
was observed that the control linker ratio remained unchanged throughout the whole titration indicating 
that there was no interaction between NADH and the dye. Interestingly, the sensor open state (when no 
NADH is present) was not similar for all linkers. The observed maximal ratio change was found to be 
Rmax = 160% or 1.6 fold ratio change. Plateau in the current setup was reached above 60 ?M NADH, a 
value larger to what was observed in the FP experiments with SNAP-DHRP with any linker. Therefore, a 
[NADH] = 200 ?M was used for all subsequent sensor opening experiments. NADH had no effect on the 
sensor labeled with L11C while NAD+ had no effect on the sensor labeled with L11 and L11C (data not 
shown). Further characterization was performed with L11. 
Furthermore, the plot (Fig 26A) was normalized on the 580nm signal (from here on referred as 
TMR signal) as signal drifts were observed upon NADH titration. Previously, FP assay presented no 
anisotropy change but total intensity changes due to environmental effects. In order to understand the 
signal drifts, the sensor was labeled with L11 only. It was titrated with NADH and a small but significant 
intensity change was observed (Fig 27A). The phenomenon could be explained by the sensor closing first 
with TMR potentially coming close to the enzyme reaching an intensity peak close to 1 ?M. When 
labeling the sensor with L11 and SiR-Halo and directly exciting SiR upon NADH titration, no fluorescence 
A 
 
B 
 
 
Fig 27 Sensor TMR assay and opening. (A) Direct excitation of the TMR dye with various concentrations of NADH as 
control. The sensor was tested in different conditions to assess environmental effects on the dye. (B) Closing of the sensor with 
NADH followed by opening with either MTX or APT. Titration with APT and MTX was performed on the sensor to assess its 
opening capacity. Control is performed with L11C and APT. Each point is the average of 3 measurement ± SD. 
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intensity change could be observed indicating no unspecific effect on the dye either by a construct 
conformational change or NADH effects on the dye. The collected data indicated that the signal was 
composed of a part of FRET and a part of environmental effects on the TMR dye. No explanation could 
be given for the factors bringing the signal down and this issue was not investigated further as it did not 
impact the sensor development. 
The sensor was labeled with L11 and was then titrated with APT and MTX at 200 ?M NADH. APT 
and MTX were titrated in order to displace the tethered ligand (Fig 27, right). The sensor was opened by 
both MTX and APT with an IC50 relatively smaller for APT than MTX showing the inhibition potential 
difference of both those drugs. Additionally, at high drug concentration a FRET ratio similar to the 
control could not be observed. It would be expected for L11C, L11 without NADH and L11 + 200 ?M 
NADH + drug to possess the same FRET ratios as the sensor should be open. This was indeed the case 
when no NADH was added to L11 but not in the presence of a drug. At high concentrations of APT, both 
L11 and L11C showed a ratio increase at 1mM explainable by the poor solubility of APT probably 
interacting with the dyes. FP experiments, more sensitive on precipitates, showed on DHPR-SNAP similar 
behaviors at relatively high APT concentrations.  
A sensor, able to quantify the interaction of a competitive drug with DHPR was created. It was 
observed that the shortest linker was performing less efficiently than the longest ones probably owning 
to its shorter size. It would be expected for it not to be able to appropriately reach the binding pocket or 
having its dye not properly oriented to produce FRET in an efficient manner. Generally, sensors with a 
high Rmax value and Z factor give the most significant and reliable results in screening campaigns. In the 
current case the obtained Rmax was fairly small (1.6x ratio change) in comparison to previously reported 
sensors (Human carbonic anhydrase: 4x233, MTX bioluminescent sensor: 13x223 & 22x234, MTX sensor 
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based on unnatural amino acids: 34x235 ) Efforts were put on increasing the Rmax value by attempting to 
incorporate unnatural amino acids, circularly permutating DHPR or modifying the sensor geometry. 
2.1.8 Sensor Optimization 
2.1.8.1 Non Natural Amino Acids 
It was hypothesized that modifying DHPR in order to incorporate close to the active site, an 
unnatural amino acid, serving as handle for later derivatization with a fluorophore, could yield an 
efficient sensor. The structure of DHPR was investigated in order to find regions prone to modifications. 
Glutamic acid 46, an amino acid proximal to the active site, located in a flexible loop, was selected to be 
modified to an Amber stop codon (modification named further on DHPR(E46X)). The suppressor system 
adapted from Lemke236 and Chin225 had shown to be successful in our lab in a subset of experiments (see 
material and methods). A generally convenient handle to install was (2S)-2-Amino-6-({[(1R,8S)-
bicyclo[6.1.0]non-4-yn-9-ylmethoxy]carbonyl}amino)hexanoic acid (BCN-lysine) as it would react with 
tetrazine in a copper-free fashion. The reaction rate has been reported to be ~ 400 M-1·s-1, ideal for fast 
protein labeling with dyes coupled to tetrazine. Four plasmids, bearing an Amber stop codon replacing 
Glu46, DHPR(E46X), DHPR(E46X)-SNAP, SNAP-DHPR(E46X) and DHPR(E46X)-p30-SNAP were produced. 
Protein expression on these constructs was either inexistent or yielded truncated products that could 
not be labeled. A GFP with an amber mutation was expressed as control. The bacterial culture had a 
characteristic yellow color indicating presence of the protein. The GFP protein was not purified and the 
idea was discontinued.  
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Fig 28 cpDHPR constructs ratio change. Three constructs based on circularly 
permutated DHPR were labeled with L11 and tested by NADH titration. Each point is the 
average of 3 measurement ± SD. 
 
2.1.8.2 Circular Permutation and Scaffold Stiffening 
The concept of modifying DHPR in order to create attachment point close to its active site was 
further evaluated. It was envisioned that circular permuting DHPR at E46 (cpDHPR) could yield a version 
able to be fused closer to the active site. It would potentially bring in closer proximity the FRET couple 
once the sensor closes increasing therefore the sensor Rmax. Using PyMOL, a linker able to link the N to 
the C termini was modeled. A (GGS)4 linker, appeared to be of the correct size and a plasmid containing 
the cpDHPR version was created. The protein expressed in satisfactory yields and an enzymatic assay on 
cpDHPR compared to DHPR was performed. Vmax and KM were measured and were found to be similar 
(DHPR : Vmax = 0.124 ?M/s, KM = 0.55 ?M ; cpDHPR : Vmax = 1.14 ?M/s, KM = 0.95 ?M). Three sensors, 
cpDHPR-ggs2-Halo-P30-SNAP, cpDHPR-Halo-P30-SNAP and cpDHPR-Halo[4:]-P30-SNAP were cloned and 
expressed. The rationale was to decrease further the distance between cpDHPR and Halo-tag and to 
decrease flexibility between Halo-tag and P30. It was observed and suggested by collaborators that the 4 
first Halo-tag amino acids could be removed (Halo[4:]) to reduce flexibility of the aforementioned fusion 
point. Increased rigidity at this point, in their case, increased the distance in the sensor open state or 
optimizing dye orientation yielding a larger Rmax. The three sensors were labeled with L11 and tested 
for closing upon NADH titration. A FRET ratio change could be observed upon titration indicating the 
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sensor closes. Rmax values increased when shortening the distances between cpDHPR and Halo-tag and 
by stiffening the Halo-tag P30 junction (Fig 28). The incorporation of Halo[4:] did increase the sensor 
open state and removal of the GGS linker the sensor closed state. Generally, the EC50 increased 
conjointly with the Rmax. However, the obtained Rmax for all of the sensors were below the value 
obtained with DHPR-p30-Halo-SNAP (Rmax = 1.6). Anyhow, these observed changes are small compared 
to what has been previously reported. Literature precedence shows that incorporation of P30 or large 
structural modifications such as circular permutation lead respectively to 4 to 6 fold231 and roughly 7 fold 
change (collaborator, unpublished data) Rmax. In the current case the Rmax changes are close or within 
the observed error. The attempted circular permutation strategy did not yield significant improvement 
and was abandoned.  
  
Fig 29 Sensors optimization based on scaffold rigidification. Two constructs lacking the (ggs)2 spacer and with different 
polyproline spacer (P15: left, P30:right) length were labeled and tested for closing upon NADH titration. Each point is the average 
of 3 measurement ± SD. 
 
As last attempt, the strategy involving shortening and stiffening the fusion points was applied on 
wild type DHPR and two constructs, DHPR-Halo[4:]-P15-SNAP and DHPR-Halo[4:]-P30-SNAP were cloned 
and expressed. DHPR-Halo[4:]-P15-SNAP was created by a mistake in the primer hybridization on the P30 
part. The two constructs were labeled with SiR-Halo and with L2, L5, L11 and L11C. Sensor closing was 
tested by titrating NADH. The obtained titration curves were similar (Fig 29) between the P15 and P30 
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bearing constructs. Again shortening and rigidifying the fusion points had only minor impact on the 
Rmax. Furthermore, even deletion of 15 proline residues had only little effects on Rmax inconsistent 
with literature precedence. Interestingly, the control linkers in both sensors had different SiR/TMR 
values.  
Optimization of the initial sensor was conducted applying methods that showed to be successful in 
previously reported sensors such as unnatural amino acids incorporation, circular permutation of the 
receptor protein and rigidification of the overall scaffold. However, in the current case none of these 
brought a substantial amelioration of the Rmax value. It was envisioned that further optimization might 
not be critical for a HTS.  
2.1.8.3 Assay validation 
The sensor and ligand couple, DHPR-Halo[4:]-P30-SNAP + L5 (Rmax = 1.63) was selected as a larger 
quantity of the linker was available and no substantial difference in Rmax was seen between L5 and L11. 
The Z factor was calculated and sample preparation and analysis was made as described in material and 
methods. A high statistical reproducibility263 of Z’ = 0.7 was found indicating that the system was suitable 
for HTS. Determination was made on the basis of two 96 well plates. 
  
- 65 - 
 
Name FRET IC50 [?M] Name Remark 
Triamterene 5.08 Daunorubicin hydrochloride Fluorescent 
Deoxycorticosterone 11.8 Doxorubicin hydrochloride Fluorescent 
Adrenosterone 15.9 Epirubicin hydrochloride Fluorescent 
Ebselen 17.4 Tetraethylenepentamine pentahydrochloride Discarded 
Testosterone propionate 26.4 Pentetic acid Discarded 
Corticosterone 26.5 Mitoxantrone dihydrochloride Fluorescent 
Mizolastine 32.2 Etomidate Discarded 
Zaprinast 29.1 Etifenin Discarded 
Clofazimine 31.7 Oxytetracycline dehydrate Discarded 
Progesterone 48.0 Alexidine dihydrochloride Discarded 
Exemestane 40.8 Sulfadimethoxine Discarded 
Praziquantel 39.3 Paclitaxel Discarded 
Medrysone 81.7 Methotrexate Known  
  Bephenium hydroxynaphthoate Discarded 
  Carbenoxolone disodium salt Discarded 
  Benserazide hydrochloride Discarded 
Table 6 Summary of the drugs discovered via the HTS campaign. In green are the drugs selected for further 
characterization. In white are the drugs that were found to interact with DHPR but which were not further 
characterized as they appeared to possess a weaker potential than APT. In red are the drugs that were discarded. A 
table containing all the structures can be found in the annex.  
 
2.2 Prestwick Library Screen 
2.2.1 Library Selection 
The library selection was made on two criterions. (i) Compounds had to be commercially available 
for further testing. (ii) Evidence showed that certain drugs provoked, in patients, symptoms related to 
BH4 deficiency119. Screening for administered drugs was of interest. Therefore the Prestwick chemical 
library was selected. This library is composed of 1280 drugs approved by regulatory agencies, and is 
chemically diverse. Compounds and their pharmacologic effects in this library also are well detailed. The 
screening campaign was performed as described in the material and method section. 
2.2.2 New DHPR Inhibitors 
Thirty hits came out in the first round of selection (Table 6). Several of these hits possessed 
similarities. Indeed, seven compounds possessed a sterone motive (deoxycorticosterone, adrenosterone, 
corticosterons, progesterone, medrysone, exemestane and testosterone propionate). Four had high 
aromatic content (daunorubicin, doxorubicin, epirubicin and mitoxantrone) and were suspected to 
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interact with the assay due to their absorbance. Finally, four compounds had characteristic chelating 
agent structures (tetraethylene pentamine, pentetic acid, alexidine and etifenin). MTX was found to be a 
hit, increasing confidence in the screen results. Furthermore, the compound triamterene (TRI), stood out 
as its structure was similar to 4-amino substituted pterins, often proven to be decent DHPR and DHFR 
inhibitors. A table containing all the drugs structures can be found in the annex. 
A second round of screening was performed without the fluorescent compounds and without 
MTX. As negative control for this round, the sensor was labeled with L11C. The rubicins and 
mitoxantrone were tested via the enzymatic assay and showed no inhibition potential. Out the 
remaining drugs, and after a second round of screening, eleven more compounds were discarded. The 
discarded compounds were either false positives or too weak binders to be of interest. The remaining 
thirteen molecules were tested for a nine points (100 to 0.78 ?M + no drug) IC50 curve. Six molecules 
possessing a sterol motif were found to interact with DHPR. A selection of four candidates was made 
based on the drugs inhibitory potential: TRI, ebselen (EBS), adrenosterone (ADR) and 
deoxicorticosterone (DCS) (Fig 30). Investigation of the drug effects on intracellular pterin balance was of 
interest. In addition, in-vitro examination of these compounds on enzymes of the BH4 metabolic 
network was pursued. These assays would shed light on the mechanisms behind potential pterin 
metabolic imbalances.  
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Fig 30 Four DHPR candidates and their IC50 curve. The four drugs were found to be the most potent DHPR inhibitors out of 
thirty candidates. Their IC50 curve, determined via the FRET assay is displayed on the right. Each point is the average of 3 
measurement ± SD. 
 
2.3 Further Candidate Characterization 
2.3.1 In-Vitro Characterization 
The inhibitory potentials of the four drugs candidates were tested on several enzymes of the BH4 
metabolic pathway. It was of interest to see if in addition to DHPR also GCH1, SPR and DHFR would be 
inhibited. Furthermore, knowing the selectivity of these drugs was important as to understand potential 
effect they might have on cell metabolism. Only drugs having an effect on the tested enzymes were 
discussed. 
2.3.1.1 DHPR & SPR & DHFR 
The candidates were tested on DHPR in an enzymatic assay and showed inhibitory potential. This 
result indicated that the interaction observed during the FRET assay was not unspecific. All candidates 
possessed an IC50 smaller than APT (Fig 31 left). The found Ki were Ki(TRI) = 5.57 ?M, Ki(ADR) = 6.3 ?M, 
Ki(DCS) = 20.1 ?M & Ki(EBS) = 28.4 ?M.  
- 68 - 
 
 
 
Fig 31 Inhibition potential assessment of the four drug candidates on DHPR and SPR. All drug candidates inhibited DHPR 
in the enzymatic assay. SPR was tested with another known inhibitor as no value had been experimentally acquired now. Each 
point is the average of 3 measurement ± SD. 
 
 
In order to assess the drug candidates inhibition potentials on SPR, they were compared to 
sulfapyridine (SPY) an inhibitor with a reported IC50 of 82 nM in a similar type of assay. No data on SPR 
had been experimentally acquired so far during this work therefore this inhibitor was used as control. As 
a result, only EBS showed inhibition potential on SPR with an IC50 of ~1 ?M (Fig 31 right). However, the 
very steep curve indicates that a potential unspecific effect is potentially taking place. This feature was 
not observed when interacting with DHPR in neither the FRET nor enzymatic assay.  
 
Fig 32 DHFR inhibition assay with the drug candidates. 
Out of the four drug candidates only TRI inhibited DHFR. Each 
point is the average of 3 measurement ± SD. 
 
The drugs candidates were tested on DHFR and it was observed that only TRI possessed an 
inhibition potential (Fig 32). An IC50 of 5.02 ?M was found resulting in a Ki of 0.13 ?M using the reported 
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KM of 2.7 ?M. The inhibition potential on DHFR is therefore roughly 40 folds higher than for DHPR. The 
inhibition of DHFR by TRI had already been reported237,238 and Ki(repo) = 0.2 ?M was found to be similar to 
our value239. 
IC50 / Ki [?M] Enzyme    
Drug DHPR DHFR SPR GCH1 
TRI 15.7 / 5.57 5.02 / 0.13 N.I N.I 
EBS 80.1 / 28.4 N.I 0.996 / - 4.67 / - 
DCS 56.6 / 20.1 N.I N.I N.I 
ADR 17.7 / 6.3 N.I N.I N.I 
Table 7 In-vitro inhibition potentials of the drug candidates towards enzymes members of the BH4 
metabolic pathway. IC50 and calculated Ki are reported as ?M. N.I.: No inhibition observed.  
 
When comparing the IC50s in the case of the FRET assay versus the enzymatic assay for DHPR, 
similar values could be observed. The obtained IC50 in the enzymatic assay where generally higher with 
a maximal difference of roughly fourfold. This might be explained by the difference of competition the 
drug faces in the two assays. In the FRET assay the tethered linker affinity for DHPR is weaker than 
6MPH4 but its local concentration is much higher. (~1mM tethered APT vs. 1 ?M 6MPH4). Table 7 
summarizes the IC50 and Ki found in the in-vitro characterization.  
2.3.1.2 GCH1 
GCH1 is a challenging enzyme to work with. GCH1 C-termini is buried inside the enzyme’s 
homodecameric structure. In order to purify GCH1, the recombinant protein was cloned with only a N-
termini Strep tag and a TEV cleavable sequence for post-purification removal as the enzyme’s N-termini 
has been shown to play a role in the interaction with GFRP. GFRP was purified in the same fashion as its 
C-terminal peptide is also buried within its core. High salt concentration was required to stabilize the 
enzyme, and precipitation occurred if the enzyme was diluted with large amounts of glycerol. Several 
tests were performed in order to characterize the enzyme. GCH1 was tested alone and in the presence of 
10eq of GFRP (Fig 33 left). The observed reaction rates were similar with and without GFRP, as reported. 
In order to assess the interaction of GFRP with GCH1, Phe was added in large excess. An increase of 
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roughly 1.5x in the reaction rate was observed similar to the reported value. Finally, temperature was 
increased from 25 to 37°C. Catalysis was reported to be performed faster at higher temperature as it 
could be observed in our case. The systems in place, the candidates were tested on GCH1 only. EBS was 
the only molecule impacting GCH1 reaction rate (Fig 33 right). The IC50 was found to be 4.7 ?M but, as 
previously seen with SPR, the hill curve was steep and inhibition went from off to on. It could not be 
excluded that enzyme precipitation occurred at the highest concentrations even though it could not be 
visually confirmed. 
  
Fig 33 GCH1 enzymatic assay and inhibition. Reaction rates for GCH1 were compared in different conditions. GCH1 was 
tested alone, with additional GFRP and Phe as well as when temperature was changed (left). GCH1 alone was assayed against 
the drugs candidates and only EBS seemed to inhibit it. Each point is the average of 3 measurement ± SD. 
 
Concerning the effects of EBS in-vitro, particularly with SPR and GCH1, they are the only enzyme 
tested possessing Cys residues close to their active site or being catalytically active. EBS has also been 
reported to be a Cys modifier indicating that the drug probably reacts with SPR and GCH1 by covalently 
modifying their Cys residues. In addition DHFR and DHPR do not possess a Cys residue close to their 
active site. EBS had no inhibitory effect on DHFR and the inhibition curves seen for DHPR, both in the 
enzymatic assay and during the FRET experiments, having regular Hill curves, point towards a non-
covalent inhibition.  
Overall, the drug candidates were tested on a selected set of enzymes part of the BH4 metabolic 
pathway. It was observed that TRI is an inhibitor of DHFR as well as DHPR. It was expected, during later 
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tests on cells that its effect would be similar to MTX or APT. EBS, as an inhibitor of both GCH1 and SPR as 
well as DHPR, was expected to present large variability in both the total amount of pterins as well as a 
change in the BH4 to BH2 ratio. DCS and ADR as specific DHPR inhibitors were expected to only shift the 
pterin balance towards an increase of oxidized biopterins. Furthermore, no tests were performed on 
PTPS, PCD and GCH1 + GFRP. Therefore, an effect, from the drugs, on the interaction between GCH1 and 
GFRP is unknown. In addition, it might be observed, during in-vivo experiments, a decrease in BH4 by 
drugs not inhibiting SPR. In this situation, it would be only an assumption to postulate that PTPS is 
inhibited. In case of PCD inhibition, since the dehydration of 4HTP occurs non-enzymatically, a significant 
change in total pterin levels or on the pterin balance was not expected. Finally, the candidates were later 
assayed on a cellular model in order to confirm these hypotheses. 
 
Fig 34 Total intracellular pterin concentration. The cultivated cells total 
pterin concentration was assayed for three lines (Fibroblast, Neuroblastoma and 
A549) with and without 100 ng/ml TNF-? and INF-?. The increase is indicated on 
top of the bars for each line. Each point is the average of 3 measurement ± SD. 
2.3.2 In-Vivo Characterization 
2.3.2.1 Controls and Method Development  
In order to test the drugs candidate in-vivo, a cellular model had to be chosen. Several cell lines 
were cultivated with cytokines for 24 h and total pterin amount was then quantified by HPLC coupled to 
fluorescence and electrochemical detection (see material and methods).  
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Human umbilical vascular endothelial cells (HUVECS) are a satisfactory choice when it comes to 
BH4 intracellular levels activations. This cell line has shown good applicability in terms of quantification 
of pterins and were used in several studies on the tetrahydrobiopterin network80,240. However on the 
practical level HUVECS are difficult to cultivate, expensive to maintain and proliferate relatively slowly. 
All attempts to cultivate them for a satisfactory period failed in our hands.  
The human adult dermal fibroblast (FIB) is known to produce large amounts of BH4 when 
stimulated with the cytokines INF-g and TNF-a (Fig 34, 188-fold), and has, as well, been used as model in 
numbers of publications on BH4 and its derivatives119,212. Furthermore, knowledge and data on the 
model had already been acquired in house. In addition, FIB have strong contact inhibition, an 
advantageous feature which allows for similar numbers of confluent cell population on plates and 
relatively convenient storage and handling. Finally, their proliferation rate is relatively fast and the media 
inexpensive. 
The neuroblastoma model has constitutive expression of the enzymes involved in the BH4 and 5HW 
biosynthesis, the precursor of serotonin. Therefore, they do not need to be activated but produce much 
less total amount of pterin. Increase of pterin concentration can be obtained upon cytokine activation 
but the increment is relatively small compared to the other model cell lines (3.5x vs. 188x).  
The epithelial lung carcinoma model A549 was also tested as it was used in house for other 
applications. Interestingly, upon activation this model produces the largest absolute amounts of pterin. 
However, A549 has not, to our knowledge, been extensively used in research on BH4. Furthermore, 
control tests on metabolic pterin imbalance were mitigated, indicating this model was not the most 
suitable for our assay. Finally, the FIB model was selected to investigate the potential effects of our drug 
candidates.  
- 73 - 
 
The effect of drugs models, on the total pterin levels and balance, was first investigated. Drugs 
known to decrease only BH4 or to increase BH2 were tested on the selected cell line. Sulfathiazole (STZ) 
and sulfamethazine (SMZ) are two drugs known to inhibit respectively strongly and weakly SPR119. They 
were shown in-vitro to have IC50 at respectively 14 nM and 16 ?M. Moreover, a roughly four fold 
decrease in in-vivo BH4 production was reported upon addition of 0.1 mM STZ along with an increase in 
neopterin concentration indicating drug permeability towards the cell membrane. However, neither BH4 
concentration decrease and neopterin increase was reported with SMZ indicating SPR inhibition was not 
obtained. Consequently, these two drugs were selected as positive and negative controls in order to 
 
 
Fig 35 Influence of drugs on pterin intracellular concentrations in FIB. Several controls were assayed on FIB in order to 
assess the effect from drugs inhibiting a specific set of enzymes. The absolute pterin concentrations are plotted in the top graph 
while the ratio BH4/BH2 was plotted in the lower graph. STZ, a known SPR inhibitor, showed a decrease only in BH4 
concentration. SMZ, usually a weak SPR inhibitor was used as negative control. No significant change in biopterin levels was 
observed. MTX and APT were used as DHFR and DHPR inhibitor. A slight decrease in BH4 was observed for MTX and an increase 
in BH2 was observed for both MTX and APT. Each point is the average of 3 measurement ± SD. 
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assess changes in absolute BH4 concentration. MTX and APT are known to inhibit in-vitro DHFR and 
DHPR and to be permeable to cell membranes124. The inhibition potentials are for MTX Ki(hDHFR) = 2.3 nM; 
Ki(DHPR) = 32 ?M and APT Ki(hDHFR) =1 nM; Ki(DHPR) =20 ?M. These two compounds were therefore selected 
as controls to assess increase in BH2 and change in the [BH4]/[BH2] ratio. 
Each of the drugs was applied on FIB at different concentration and pterin levels were quantified 
after 24 h by HPLC coupled to fluorescence and electrochemical detection (see material and methods). 
Generally, when no drug was added, BH4 concentration was predominantly higher than BH2 and 
biopterin (Fig 35). Total pterin levels at low drug concentration were in each tested experiment 
significantly higher compared to the drug-free setup. As predicted, BH4 levels in the case of STZ, 
decreased in a dose dependent manner with a maximal ten fold decrease compared to the lowest drug 
concentration. The obtained IC50 for this titration was roughly 160 ?M, a value ten fold higher than the 
reported one. Over the whole titration, BH2 levels were also higher than in the drug free case. Overall, 
steady BH4 and BH2 concentrations were observed for SMZ indicating the drug inability to strongly 
inhibit SPR.  
A dose dependent increase in BH2 concentration was observed upon both MTX and APT titration. 
However, a BH4 concentration decrease upon MTX increase could also be observed at 1 ?M. This change 
in BH4 concentration was unexpected as only enzymes responsible for the recycling and salvage of BH4 
should be affected. However, in the case of APT no BH4 decrease was observed and the BH2 levels 
started decreasing at similar concentration than MTX. In both MTX and APT experiments biopterin levels 
were slightly higher compared to cases involving other compounds. 
Finally, spiked samples injected at the first and last run consistently showed a partial transformation 
of BH2 to biopterin. BH4 and total amount of pterin however remained stable over the nine hours of 
analysis usually performed. Therefore, in all experiments, the pterin [BH4]/[BH2] ratio was compared to 
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the [BH4]/([BH2] + [biopterin]) ratio in order to ensure no significant value discrepancy. The observed 
ratios were never significantly impacted by a degradation of BH2. It was also shown that the half-life of 
BH2 degradation in the presence of 6.5 mM DTT and TCA is ~5 h11. Furthermore, maximal sample 
residence time at room temperature was of 2.25 h minimizing potential BH2 conversion the solutions 
being stored at -80 °C. Additionally, the samples were spiked with 1 ?M pterins, a quantity largely higher 
than the value measured endogenously. At such concentration BH2 might degrade faster. 
 
Fig 36 Conversion from number of cells per ml to protein 
concentration. A conversion scale on two models, neuroblastoma 
and FIB was performed. Each point is the average of 3 
measurement ± SD. 
 
Generally, literature reports metabolite concentration in cells as nmol/mg of protein therefore a 
conversion scale was made in order to transform the units of fmol/cell (Fig 36). A value of 8.2E-7 ± 4.3E-8 
mg/cell was found, converting total pterin content in the order of 0.1 to 0.3 nmol/mg of protein. These 
values were lower but close to the reported values of 0.3 to 0.4 nmol/mg of protein in the case of 
fibroblasts. Total protein amount per cell was also measured for the neuroblastoma model as a 
comparison. A value of 2.2E-07 ± 2.2E-8 mg/cell, coherent with the fact that this cellular model is smaller 
than FIB, was found.  
- 76 - 
 
In summary, the applied method allowed for quantification of pterins. FIB showed to be the most 
favorable cell line for assays on pterin metabolism. Indeed, they were shown to generated large amounts 
of endogenous pterins upon incubation with cytokines. Total pterin concentration was generally variable 
between each run and standard deviation on absolute values was rather high. Pterin ratios were usually 
reproducible and effects upon drug addition visible. It was seen that spiked BH2 had a tendency to 
oxidize to biopterin after long periods of incubation in the lysis buffer while BH4 and total pterin 
concentration stayed stable. This effect was negligible on authentic samples as the incubation time and 
BH2 concentration was much lower. Pterin levels were modified according to the drug incubated. BH4 
decreased in the presence of STZ, BH2 increased in presence of with MTX and ATP and pterin levels 
remained unchanged with SMZ. The [BH4]/[BH2] ratio decreased in a dose dependent fashion for both 
MTX and STZ. The most dramatic ratio decrease for MTX was influenced by the BH2 increase while STZ 
was only influenced by the relatively large BH4 decrease. This observation was consistent with the drug 
mechanism of action. SMZ ratios stayed generally similar to those observed in the drug free case, 
consistent with the lack of BH4 concentration changes observed. Additionally, total pterin concentrations 
were found to be similar to what had been reported119. Furthermore, the IC50 found for STZ here was 
higher to what had been reported119 due predominantly to the difference in cell type used and the 
detection method. 
2.3.2.2 Drug Candidates Assay 
The four drug candidates were applied at different concentration on FIB and incubated for 24h. 
TRI showed to be toxic at concentration of 100 ?M and above, which can be explained by the 
impairments in causes on DNA metabolism. A report showed that 80 ?M TRI was enough to cause 
dissolution of human lymphoma cells241. Cells were usually detached and deformed at such 
concentrations while 50 ?M seemed to have no significant deleterious effects. Trypan blue assay showed 
good cell survival and cell shape was similar to cells in the drug free condition. TRI induced a strong dose 
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dependent BH2 increase similar to levels observed in the case of MTX and APT. At 50 ?M BH4 
concentration decreased at concentration similar to BH2 (Fig 37). This decrease was unexpected and 
might be linked either to unspecific effects on the de-novo BH4 synthesis or potentially as an indication 
of toxicity even though the cells were still alive. In the most extreme case the [BH4]/[BH2] ratio was 
found to be equal to unity whereas the lowest ratio observed for MTX was roughly six.  
EBS showed to be toxic at concentrations above 10 ?M. At 50 ?M cells were still attached but 
usually broke into fragments when trypsin was applied. Pterin concentrations were not showing a 
significant change upon titration, more clearly reflected by the steady ratios obtained.  
ADR and DCS had no notable cell toxicity at 50 ?M. This maximal drug concentration was chosen 
for ADR and DCS in order to be comparable with TRI. Neither of the compounds could alter pterin 
concentrations or ratios. Generally, biopterin was not affected by any of the drugs concentration and 
remained constant within all experiments. It was notable that ratios and total pterin concentration 
varied between analysis rounds as seen previously in the method setup. As pairs EBS and TRI did not 
have the same total amount of pterin with respect to ADR and DCS at their lowest concentration. Finally, 
the only compound showing potential in generating metabolic pterin imbalance was TRI. 
  
Fig 37 Influence of drugs candidates on pterin intracellular concentrations in FIB. An increase of BH2 takes place in a dose 
dependent fashion in the case of TRI. BH4 decreases only significantly at 50 ?M. The ratio BH4/BH2 was plotted on the right. 
Each point is the average of 3 measurement ± SD. 
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2.4 Discussion on the Discovered Compounds 
Interest was initially put on the development of tool compounds for the inhibition of DHPR and 
study of administered drugs side effects that could be linked to the BH4 metabolic network. Here, the 
results obtained with each of the four candidate drugs are discussed and a description of their 
mechanisms of action or usage is provided. 
2.4.1 On Triamterene 
2.4.1.1 Mechanisms of Action 
Triamterene is a diuretic agent used for the treatment hypertension and edema242. 
Mechanistically, TRI blocks Na+ reabsorption and lowers K+ secretion. It acts on the renal transport of 
sodium by blocking, in the renal collecting tubules, the Na+ channels. TRI also inhibits the nephrotrophic 
effect of aldosterone. Classically, when taken alone, 50-300 mg/day of TRI is ingested. Fifty to sixty 
percent of it is bound to plasma proteins and is as well rapidly metabolized. It has been reported that 
only 3% of the drug was excreted unchanged. Furthermore, TRI is often administered with 
hydrochlorothiazide an antihypertensive agent. Hydrochlorothiazide is a sulfa drug, but has not been, to 
our knowledge, reported as a SPR inhibitor. It does however possess similar structural features as 
reported sulfa drug derived SPR inhibitors.  
2.4.1.2 Relevance 
To our knowledge, TRI has never been reported as a DHPR inhibitor. As presented, the drug is 
the best DHPR inhibitor in-vitro. In-vivo, data show maximal pterin imbalance was observed in the 
presence of TRI. The BH4/BH2 ratio observed at 50 ?M was roughly 1, a value that is lower than the 
lowest ratio observed in the case of MTX and APT. However, TRI is not strictly selective to DHPR and part 
of its potency might be due to its effect on DHFR as well. The fact that TRI has a better potency on DHPR 
than MTX and APT in-vitro might explain lower obtained ratio value. Generation of such pterin imbalance 
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is of interest when studying oxidative stress in cellular models. At such low ratio, NOS becomes 
uncoupled and oxidative stress ensues. However, in mammalian models, at safe dosages, maximal 
intracellular and plasma concentration are expected to be low. Furthermore, the fast metabolization 
decreases as well total TRI amount. Therefore, it is not expected for TRI to have significant effects on the 
BH4 metabolic pathway. It would be of interest to study the effects of other bicyclic polyaza diuretics on 
members of the BH4 metabolic network as they might prove to be inhibitors.  
2.4.2 On Ebselen 
2.4.2.1  Mechanisms of Action 
 
Fig 38 EBS catalytic mechanism. EBS peroxidase-like activity takes place via two different cycles. Cycles A & B by first 
reacting with and hydroperoxy, cylcles C,D & E by first reacting with a thiol.  
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Ebselen (EBS) was first described as a seleno-organic compound with glutathione peroxidase-like 
(GSH Px-like) and antioxidant activity243. GSH Px, a selenocysteine bearing enzyme, was shown to be able 
to catalyze the degradation of several types of hydroperoxides and showed to be a potent defense 
against oxidative challenges. EBS performances in vitro as a GSH Px analogue were demonstrated with 
H2O2, t-butyl hydroperoxide and to a larger extend hydroperoxy-lipids in the presence of GSH, GSSG 
reductase and NADPH244. No activity was observed in absence of GSH. In addition, EBS has the ability to 
react with various other thiols such as DTT, N-acetyl-L-cysteine, dihydrolipoate. Later on, EBS propensity 
as being a moderate free radical and singlet oxygen quencher as well as a potent peroxynitrite scavenger 
was demonstrated245,246,247. Model experiments indicated that the drug could protect liposomes, 
microsomes and some organs against oxidative stress248. Furthermore, low toxicity in animals was 
observed owning to the lack of selenium bioavailability249 and almost complete binding to serum albumin 
(90%)250. Therefore, organoselenium drugs could be of clinical interest in diseases involving oxidative 
stress.  
Mechanistically, EBS mediated conversion of peroxides is complicated and not yet fully characterized 
(Fig 38). Some of the presented pathway could be favored in-vivo due to concentrations of thiols and 
peroxides differing from in-vitro experiments. Two main reaction paths were proposed initiated (Fig 38 
top) via peroxide selenium oxidation or via the thiol adduct (Fig 38 bottom). Peroxide initiation was 
proposed to proceed with (cycle B) and without (cycle A) ring opening. When thiol is in excess, the 
reaction can process via a mix of selenol and selensulfide form (cycle D) or via the reaction of two 
selensulfide forming a diselenide (cycle E)251. In addition, high reactivity of selenol towards peroxides 
closes the cycle via the selanol intermediate (cycle C). In classical peroxidase experiments selenol was 
shown to be the dominant form proceeding to EBS formation via cycle C. Finally, such versatile chemical 
interconversions might be beneficent to EBS metabolic stability. 
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EBS was also shown to be an inhibitor of enzymes involved in inflammation such as NOS, protein 
kinase C, NADPH oxidase, lipoxygenases and H+/K+-ATPase. Furthermore, numbers of reports have shown 
how organic diselenides could inhibit enzyme bearing thiols vicinal to their active site252. Additionally, it 
was shown that EBS toxicity in mice is related to its administration means and probably owning to 
depletion of said endogenous thiols-bearing enzymes. EBS has been shown to be an anti-inflammatory 
agent in numbers of animal studies. The action mechanism is believed to be linked to an attenuation of 
peroxynitrite accumulation, or inhibition of certain pro-inflammatory lipoxygenases. Another effect of 
EBS administration is antinociceptive action. The drug was also tested for its effect on neuropathic and 
inflammatory pain. As example, BH4 level decrease and nitrosative stress has been observed in plasma 
of nephropathic type II diabetic rats, concomitant with previously described metabolic pterin imbalance 
and oxidative stress phenotypes253. At 22 weeks, sclerosis, proteinuria nitro-tyrosinated proteins and 
decreased renal levels of BH4 and an increase in BH2 were observed, a phenomenon absent in lean rats. 
EBS admission was shown to decrease BH2 and increase BH4 to near absolute basal levels but leave 
qBH2 as roughly 20% of total pterin content254. A study on the effects of EBS in acute ischemic stroke in 
adults showed the drug potency to slightly improve the stroke outcome. As ROS have been shown to 
play a role in permanent brain damage due to ischemia it was correctly postulated that EBS could be of 
clinical value255. Further evidence confirming EBS role as oxidative and nitrosative stress regulator has 
been gathered in numbers of animal model studies256.  
2.4.2.2 Relevance 
As mentioned previously EBS is a cysteine modifier and reacts with protein thiols. It therefore 
not surprising that in-vitro effects can be observed on several enzymes. GCH1 and SPR both possess Cys 
located close to the active site or needed to perform catalysis. However, no reduction of total pterin was 
observed in-cellulo. As seen for SPR and GCH1 in-vitro, 10 ?M EBS should totally inhibit the enzyme 
activities. DHPR showed to be a target in both the FRET and the enzymatic assays indicating it could be a 
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true target. DHPR only possesses Cys that are either buried or far from any biding pocket. Furthermore, 
it is not surprising to see no effect on cellular assay. Reports indicate that EBS can bind to proteins such 
as serum albumin, be transferred in the cells and detach in the cytosol or to be transferred to other 
proteins250,257. However, as EBS is expected to be mostly bound to albumin, it can be expected that a 
large part of the added compound is not free to access the cells. Additionally, the maximal possible 
viable drug concentration tested of 10 ?M is not significantly higher than the Ki. Also no experiment 
measuring the internal cell concentration was performed therefore no conclusions can be drawn on a 
potential accumulation of the drug.  
2.4.3 On Adrenosterone and Deoxycorticosterone 
ADR is a steroid hormone produced by the adrenal cortex. As endogenous molecule, it possesses 
androgenic potential. ADR is commonly taken as a dietary supplement for athletes willing to drastically 
increase their muscular weights and fat loss258. Classically, oral dosage of such compound, for cosmetic 
concerns, is ranging from 0.3 to 0.9 g/day over periods of 5 to 9 weeks259. DCS is, when administered, a 
neuroactive steroid acting as a sedative-hypnotic agent. It inhibits the CNS excitability by interacting with 
?-aminobutyric acid (GABA) receptors260. Endogenously, DCS is a biosynthetic precursor of 
corticosterone. 
To our knowledge, the steran motif has never been reported to have direct interaction with enzymes 
from the BH4 metabolic network. Indeed GCH1 on the transcriptional level has been reported to be 
impacted by estradiol82 but no competitive inhibition has ever been reported, for any of the remaining 
enzymes. It is unexpected for endogenous steroid hormones to affect the BH4 metabolic pathway and 
especially not DHPR as their concentration in the cytosol is in the nM range. Classically, membrane 
permeability coefficient for steroid hormones is low (10-4 cm/s)261. It was reported that steroids are 
generally protein and membrane bound and that the free compound percentage was a maximum of 
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4%262. In the presented case fetal bovine serum composed 10% of the medium. This represents roughly 
50 ?M of protein concentration in the culture medium263, equal to the maximal concentration of added 
drug. It is expected for ADR and DCS to have been principally accumulated at the cellular membrane or 
to proteins part of the culture medium. Therefore, concentration of the molecules in the cytosol is 
expected to be low. Consequently DHPR inhibition shall not have taken place even at larger 
concentration than 50 ?M since the IC50 is in the 10th of ?M.  
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Chapter 3. Conclusion 
3.1 Achievements  
Based on a pipeline established in this work, a semisynthetic FRET sensor for investigating the 
interaction of DHPR with small molecules was developed. The pipeline consisted of increasing molecular 
and proteic scaffold complexity by adding elements to the system and testing the effect of each of these 
modifications. This approach allowed to quickly troubleshoot the development and guided the rational 
design of the sensor. Computational modeling was as well performed to shed light on structural clues 
further reinforcing planning towards a successful system. Once the sensor operational, a high 
throughput screen was performed in order to discover DHPR binders. Thirteen molecules were shown to 
interact with the enzyme. The four most potent compounds, TRI, EBS, ADR and DCS were selected for 
further investigation. Each of the candidates was assayed in enzymatic assays against DHPR, DHFR, SPR 
and GCH1. It was shown that TRI was the most potent inhibitor against DHPR but was also active against 
DHFR. EBS was disrupting catalytic activity of enzymes possessing Cys residues close to their active sites. 
ADR and DCS were selective towards DHPR. Later, a method was set up for the quantification of pterins 
in mammalian cells. It was possible via reversed phase HPLC coupled to fluorescence and 
electrochemical detection to separate and quantify biopterin, BH2, pterin, neopterin, xanthopterin and 
BH4. The drug candidates were incubated with cytokine activated FIB in order to study their effects on 
metabolic pterin balance. Biopterin, BH2 and BH4 levels were quantified and the ratio [BH4]/[BH2] was 
calculated. It was observed that only TRI induced a significant effect on the pterin balance oppositely to 
other drug candidates. It was hypothesized that the pterin imbalance, generated by incubation with TRI, 
is significant enough, in the case of cells, to produce partial NOS uncoupling. Such feature can be of 
interest in the study of cellular oxidative stress. However, TRI is not expected to have effect on vertebrae 
BH4 metabolic network since most of the drug is quickly metabolized.  
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3.2 Future Development 
The method used for pterin quantification did not focus on the quantification of qBH2. The 
quantification of the molecule could be of interest to picture the percentage of oxidized pterin 
generated by DHPR with respect to DHFR. A method has been reported to satisfy this requirement, could 
be included in the detection but would double the analysis time and diminish the overall detection 
sensitivity264. Furthermore, addition of an internal standard would ameliorate the reproducibility of the 
obtained results. Some synthetic pterin such as 6MPH4 or 6,7MPH4 could have been used. 
The structural sterone motif appeared multiple times as selective inhibitor for DHPR. Development 
of more potent sterone derived DHPR inhibitors could be performed by structure activity relationship. 
This suggestion might be of interest for in-vitro studies. The inherent poor ability of sterones to cross the 
membrane will make development of cell permeable and potent candidates a challenge. Furthermore, it 
cannot be excluded that such molecules would in the process interact with nuclear receptors leading to 
unwanted side effects. 
EBS, even though it did not influence the metabolic pterin imbalance in cells, could be further 
studied in rodent models. Indeed, several mechanistic features are of interest with respect to oxidative 
and nitrosative stress. In the case of neuropathic pain, quantification of nitro-peroxides and pterin 
balance could be of interest. EBS, in the case of vitiligo, could be a candidate for diminishing H2O2 and 
potentially restoring pigmentation. Topical administration of EBS with thiols could reverse skin 
depigmentation locally. Unfortunately, this hypothesis seems incorrect as a study shown that 20 mM EBS 
applied topically promotes dermal depigmentation265. Furthermore, there is potentially a way for EBS to 
rescue BH4 oxidation. A control of interest would have been to test EBS in conjugation to TRI. BH4/BH2 
ratios could potentially increase shedding light on EBS mechanism. 
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Chapter 4. Material and Methods 
4.1 General Methods 
4.1.1 Cloning 
All the engineered plasmids were designed using the software Geneious. Gene sequences were 
ligated together using the Gibson Assembly method. The vectors used were based on pET-51b(+) 
(Novagen). PCR amplifications were carried using New England Biolab Q5 Hot Start High-Fidelity DNA 
Polymerase. Transformation was carried in Lucigen E. cloni 10G electrocompetent cells. The clones were 
sequenced using Sanger Sequencing proposed by GATC-biotech (www.gatc-biotech.com). Primers were 
synthetized by Microsynth AG (www.microsynth.ch) and were ordered as 100 ng/?l solutions. 
4.1.2 Protein Expression 
BL21(DE3) cells (New England Biolab) were transformed with purified plasmids by electroporation. 
Bacterial cultures were grown at 37°C in 100 ml auto-inducible terrific broth supplemented with 25 mM 
ammonium sulfate, 2 mM magnesium chloride, 0.2% lactose and 0.05% glucose for 5 hours followed by 
17h at 25°C. The cells were harvested by centrifugation, the obtained pellet was lysed by sonication. The 
debris and insoluble parts were discarded after centrifugation. The proteins of interest were purified by 
Ni-NTA (Machery Nagel) and Strep-Tactin (iba) chromatography following the provided protocols. Purity 
was assessed by electrophoresis on polyacrylamide gels. Quantification of protein concentration was 
performed by absorbance measurement at 280 nm. The extinction coefficients were estimated using 
Geneious’ statistics tool. 
4.1.3 Protein Labeling 
4 ?M of self-labeling protein was allowed to react for 90 minutes at room temperature with 8 ?M of 
its corresponding TMR-conjugated tag. The reaction was performed in 400 ?l Tris-HCl 40 mM, pH 7.4, 0.5 
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mg/ml BSA buffer. The proteins were purified from the excess tag by centrifugal filter. The obtained 
concentrated solution was washed four times with Tris-Cl 40 mM, pH 7.4 to ensure total removal of the 
excess tag. The protein concentration, in the resulting solution, was measured on the TMR absorbance. 
Control of labeling efficiency was performed by adding a dye of different color (BG-Alexa488 and Halo-
Alexa488) to a purified labeled sample. The quantification was performed by running the samples on 
polyacrylamide gels. (See appendix protein gels and yields) 
4.2 Enzymatic Assays  
If not explicitly specified, the buffer used in all the enzymatic assays was Tris-Cl 40 mM, pH 7.4, 0.5 
mg/ml BSA and the temperature was 22°C. All assays were performed in a transparent Greiner 96-well 
plate and measured with a Tecan Infinite M1000 spectrophotometer. Ki was calculated for DHFR and 
DHPR based on the equation (eq 1) 
     ?? ? ??????? ?????      (eq 1) 
Where IC50 is the concentration at half inhibition, [S] is the substrate concentration, KM is the Michaelis-
Menten constant. This approximation is only valid in the case of competitive inhibition266.  
4.2.1 DHPR Cytochrome-c Based Assay 
DHPR enzymatic activity was assayed following Arai et. al. method267. The enzymatic conversion of 
qBH2 to BH4 is followed by the quick reduction of FICC to FOCC by BH4. FICC reduction is followed by 
reading the increasing FOCC absorbance signal at 550nm. The experiment is run for 40 minutes and 
recorded at 10 seconds intervals in 200 ?l buffer containing 50 ?M FICC, 1 ?M 6MPH4, 20 nM DHPR, 50 
?M NADH and selected inhibitor concentration. A control lacking DHPR is ran in parallel to assess the 
rate of non-enzymatic reduction of qBH2 by NADH. The extinction coefficient used for FOCC and NADH 
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are respectively 29500 (reduced, 550 nm, H2O) and 6220 (340 nm, H2O) L·mol¯¹·cm¯¹. Generally, 50 ?M of 
FOCC and FICC in buffer are measured in isolated wells to assess reaction completion.  
4.2.2 DHFR Assay 
The enzymatic conversion of dihydrofolate (FH2) to tetrahydrofolate (FH4) is followed by the 
resulting decrease in signal at 284 nm. The experiment is run for 30 minutes and recorded at 10 seconds 
intervals in 200 ?l buffer containing 50 nM DHFR, 100 ?M FH2, 300 ?M NADPH and selected inhibitor 
concentration. A control lacking DHFR is ran in parallel. The extinction coefficients used for FH2 and 
NADPH are respectively 28000 (284 nm, H2O pH 12) and 6220 (340 nm, H2O) L·mol¯¹·cm¯¹.  
4.2.3 SPR Assay 
The enzymatic conversion of sepiapterin to BH2 is followed by the resulting decrease in signal at 420 
nm. The experiment is run for 30 minutes and recorded at 10 seconds intervals in 200 ?l buffer 
containing 50 nM SPR, 100 ?M sepiapterin, 300 ?M NADPH and selected inhibitor concentration. A 
control lacking SPR is ran in parallel. The extinction coefficient used for sepiapterin is 10400 L·mol¯¹·cm¯¹ 
(420 nm, H2O).  
4.2.4 GCH1 Assay 
The assay was adapted from Hussein et al.72. The buffer was 100 ?M Tris-Cl, 100 ?M NaCl, pH 7.3. 
Reaction was ran with 0.25 ?M GCH1, 100 ?M GTP and selected inhibitor concentration. When added, 
[GFRP] = 2.5 ?M & Phe = 100 ?M. Total reaction volume was 200 ?l. Reaction rate was followed by 
appearance of the H2NTP at 340 nm. The experiment was run for 60 min and recorded as 10 s intervals. 
The extinction coefficient used for GTP was 14200 L·mol¯¹·cm¯¹ (252 nm, H2O pH 7). 
  
- 90 - 
 
4.3 Fluorescence Polarization 
FP assays are performed in a black opaque Greiner 96 half-well volume, non-binding, plate using 
the Envision 2103 Multilabel Reader. The assay was run at 50 nM labeled enzyme concentration in a 
total volume of 40ul. The buffer used was Tris-Cl 40 mM, pH 7.4, 0.5 mg/ml BSA and measurement was 
performed at 22°C. The filters are used according to the dye emission and excitation characteristics.  
4.4 High Throughput Screen 
The DHPR-[4:]HALO-pro30-SNAP sensor labeled with Sir-Halo and BG-EG5-TMR-(CH2)6-APT (L5) was 
screened against the Prestwick library (1280 compounds). Screening took place at the Biomolecular 
Screening Facility in EPFL. The plates used were black opaque Greiner 96 half-well volume and read with 
Tecan Infinite F500 (excitation 520 nm, emission 667 nm). Z’ factor263 determination was calculated 
following equation 2 with 96 positive and 96 negative control measurements homogeneously spread on 
two plates.  
?? ? ? ?? ??????????????????????????????????      (eq 2) 
Where dev is the standard deviation, ABS is the absolute value and avg is the average. Z values 
between 0.5 and 1 denote an excellent assay. The negative control was 40 ?l Tris-Cl 40 mM, pH 7.4, 0.5 
mg/ml BSA, 200 ?M NADH, 50 nM sensor. 200 ?M APT was supplemented to the previous solution for 
the positive control. 80 compounds at 10 ?M were tested per plate. The compounds were kept as 100 
mM DMSO stocks and were diluted to 10 ?M working concentration. 16 wells were used for positive and 
negative controls. Each plate was made in duplicate. The obtained hits, defined as a compound inducing 
FRET change more than 3x the standard deviation of the positive control measurement, were tested a 
second time and confirmed against a different control: DHPR-[4:]HALO-pro30-SNAP labeled with Sir-Halo 
and BG-EG11-TMR-COOH (L11C) . A titration curve for each confirmed hit was performed in triplicate 
between 100 ?M and 0.78 ?M.  
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4.5 Cell Culture 
Adult human dermal FIB were purchased from Lonza. Human neuroblastoma (SK-N-BE(2)) and A549 
were purchased from ATCC. The aliquots were thawed at 37°C directly after reception and were 
transferred in a 75 cm2 plate containing for FIB and A549 25 ml, 37°C DMEM Glutamax + 10% heat 
inactivated FBS (all from Gibco) and for the neuroblastoma 25 ml DMEM/F-12, Glutamax + 10% heat 
inactivated FBS (all from Gibco). Cells were cultivated as a main seed plate in 75 cm2 plates (TPP) and at 
each passage cells were split 10 times. Prior to analysis cells were cultivated in 6well plates (9.8 cm2 / 
well) in 2 ml of their respective medium.  
4.6 HPLC Fluorescence and Electrochemical Detection 
The analytical setup consisted of the Shimazu Prominence system coupled to a Thermo Scientific 
Ultimate 3000 RS electrochemical detector (Fig 39 A). The whole system was controlled using 
Chromeleon 7.2 with Shimadzu drivers for Chromeleon. HPLC running buffer was prepared as follows: A 
mQ water solution of 6.5 mM NaH2PO4, 6 mM Citric acid, 1 mM sodium octyl sulfate (OSA), 1.5 mM 
diethylenetriaminepentaacetic acid was prepared and brought to pH 3.0 and 3.5% v/v ACN was added. 
The solution was flown circularly during 48 h at 2 ml/min over two 5011 ESA electrochemical cells set at 
1 V & 100 ?A in order to oxidize all contaminants. To this solution DTT was added to 1 mM prior usage. 
The HPLC run was conducted in isocratic mode over a 4.6x150 mm Waters Atlantis dC18, 3 ?m column 
protected with Vanguard cartridges at 1.6 ml/min. The column was thermostated at 30°C and injection 
volume was 50 ?l. The column allowed separation of several types of pterins. Biopterin, BH2, BH4, 
xanthopterin, neopterin and pterin were all separated to baseline. Furthermore, a clear conversion of 
BH2 to biopterin took place upon passage in the electrochemical detector (Fig 39 B). The shoulders 
observed in Fig 39 B were later corrected using ThermoFisher Viper Fingertight fitting to obtain small 
width symmetrical peaks (Fig 39 C). Fluorescence was recorded with the excitation wavelength set at 350 
nm and the emission wavelength set at 450 nm. Detector sensitivity and gain were set to medium and 
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4x. The two dual channel 5011A electrochemical cells were set at 450, 600, 800 & 1000 mV with 
automatic current parameterization. Determination for the oxidation voltage of BH4 was confirmed by 
performing an hydrodynamic voltage curve. Biopterin, BH2 and BH4 retention times were compared 
with authentic samples (Schirks Laboratory) (Fig 39 B,C). Biopterin was quantified via fluorescence; BH2 
was converted post-column via electrochemical oxidation (800 mV) to biopterin and quantified via 
fluorescence. Finally, BH4 was quantified on the 450 mV electrochemical detector channel. Detection 
limit of BH2 and biopterin was 1 nM being linear at least up to 1 ?M. Detection limit of BH4 was 40 nM 
being linear at least up to 10 ?M. Samples are usually run as batches of 9 aliquots while the next batch is 
kept at -80°C in order to preserve the samples from oxidation. 
4.7 Pterin Quantification 
Pterin quantification was made by means of HPLC coupled to electrochemical and fluorescence 
detection. The protocol was adapted from Biondi et al.10, Howells et al214 and Fismen218 et al. FIB were 
cultivated in 6 well plates (9.8 cm2) until reaching 50% confluence. Medium was removed and replaced 
with 1 ml fresh medium supplemented with 100 ng/ml recombinant human interferon-? (INF-g, R&D 
Systems Europe Ltd), 100 ng/ml recombinant human tumor necrosis factor-? ( TNF-a, Sigma Aldrich) and 
drugs of interest (triamterene, ebselen, aminopterin, methotrexate, adrenosterone, 
deoxycorticosterone, sulfatiazole and sulfametazine). Cells were incubated for 24 h. Medium was 
removed and wells were washed with 1 ml PBS without Ca2+ and Mg2+ (Lonza). Cells were detached with 
300 ?l trypsin (Sigma), collected, and the remaining cells were collected by addition of 700 ?l PBS per 
well. The cells were quantified using Scepter Cell Counter (Millipore), 60 ?m sensor and gating from 13 
to 31 ?m. The collected cells were pelleted by centrifugation (2.5 min, 2500 RCF, 4°C) and the 
supernatant was discarded. The pellet was washed and centrifuged (2.5 min, 2500 RCF, 4°C) once with 
150 ?l ice cold of 50 mM Tris-Cl, 1 mM DTT, pH 7.4. Cells were lysed using 90 ?l of ice cold 200 mM 
trichloroacetic acid, 40 mM ascorbic acid, 1 mM EDTA, 5 mM DTT. The solution was sonicated for 10 
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seconds in a sonication bath to dissolve the cell pellet before being centrifuged (10 min, 20000 RCF, 4 
°C). The supernatant was transferred to HPCL analysis vials and 50 ?l were injected. 
A 
 
B 
 
C 
  
 Fig 39 Pterin quantification method based on HPLC coupled to fluorescence and electrochemical detection. (A) 
Schematic view of the process. The HPLC is run in isocratic mode at 1.6 ml/min and 50 ?l of sample is injected. The column 
is thermostated to 30 °C and the four analytical cells on the electrochemical detector is set to 450, 600, 800 and 1000 mV. 
On the fluorescence detector the excitation and emission wavelengths are set to 350 nm and 450 nm, respectively. Two 
wavelengths for the absorbance are set to 260 and 320 nm. BH4 is detected on the analytical cell at 450 mV. Biopterin is 
detected by fluorescence. BH2 is oxidized by the analytical cell to biopterin at 800 mV and detected by fluorescence (B) 
Separation of a solution in water of 5 pterins. Biopterin (biop), neopterin (neop), xanthopterin (Xantho) BH2 and pterin 
were injected separately and separated as a mixture with and without electrical potential applied. (C) Cell lysis sample 
(left) Biopterin and BH2 are detected by fluorescence and BH4 is detected (right) by electrochemical detection at 450 mV.  
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Routinely, 24 samples are run in a day and a sample spiked with Biopterin, BH2 and BH4 is run at 
the first and last daily injection to control for potential degradation. The column is then flushed with 
decreasing polarity solvents with 10 volumes of ACN, 10 vol. 80:20 MeOH:ACN, 20 vol 10:90 MeOH:DCM 
and reversed back to ACN. This ensures removal of hydrophobic cell lysate residues and keeps 
reproducibility in retention times. 
4.8 In-Silico Docking 
The in-silico docking of qBH2 in DHPR was performed with the AutoDock Vina algorithm 
(http://vina.scripps.edu). qBH2 and MTX were drawn in 2D using ChemDraw 15.0 and then converted to 
3D objects in *.pdb format using Chem3D (http://www.cambridgesoft.com). *.pdb molecule structures 
were optimized using OpenBabel (http://openbabel.org) and the force field algorithm Ghemical. DHPR 
(pdb: 1HDR) was prepared as lock using MGLTools (http://mgltools.scripps.edu). Water molecules on the 
structure were removed and polar hydrogen atoms were added. The modified DHPR structure was saved 
as *.pdbqt files, an enhanced *.pdb format taking into account bond flexibility, atom polarity and charge. 
Using MGLTools all rotational and rigid bonds within the small molecules were defined. The structures 
were saved as *.pdbqt as well. The search space box was defined around DHPR’s active site using 
MGLTools enclosing all vital residues as well as NADH. The configuration file was written as presented on 
the official website and calculations were performed on a desktop computer (Intel(R) Core(TM) i5-2550K 
CPU @ 3.40 GHz (4 CPUs), ~3.4 GHz, 8192 MB RAM, AMD Radeon HD 6450) running under Linux Mint 
17.1. Results were visualized using PyMOL (https://pymol.org/) 
4.9 Unnatural Amino Acids Incorporation 
The used method was adapted from the Lemke236 and Chin225 groups. Two plasmids were used. The 
pEvolv-pylRS/AF plasmid was carrying the modified tRNA/synthetase pair while the pBAD carried the 
gene of interest. Modification of DHPR Glu 46 in pET-51b(+) plasmids was performed by point mutation 
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with a NEB Q5 Site-Directed Mutagenesis Kit Quick Protocol (E0554) to insert an Amber stop codon. The 
gene of interest was afterwards cloned into pBAD. The transformed cells were 50 ?l of DH10B cells 
transformed with 5 ng of pEvol-pylRS/AF (Chloramphenicol (CMP) resistance) and 5 ng of pBAD 
(Ampicillin (AMP) resistance). Pre-culture was performed adding 500 ?l transformed bacteria to 3 ml LB 
medium containing 50 ?g/ml AMP and 25 ?g/ml CMP at 37 °C overnight. The pre-culture (1 ml) was 
added to 30 mL TB medium with AMP (50 ?g/ml) CMP (25 ?g/ml) and incubated at 37°C. When culture 
reached OD = 0.4, 2 ml freshly prepared 1 mM BCN-lysine was added. Culture was induced with 0.2% 
arabinose at OD = 0.6. After 5 h incubation at 37 °C the cells were centrifuged at 4000 g, 15 min, 4 °C. 
Purification was performed as previously explained. No BCN-lysine click-coupling was performed as no 
protein was obtained. 
4.10 Protein content per Cell 
Cells were cultivated upon confluence in a 75 cm2 plate and detached. The plate content was 
transferred in a 12 ml tube and centrifuged (1000 g, 5 min, 4 °C). The supernatant was discarded, the 
pellet suspended with 2 ml PBS to be centrifuged again (1000 g, 5 min, 4 °C). This operation was 
repeated 3x to remove all protein and amino acids content. The pellet was suspended in 2 ml PBS and a 
2x dilution series was performed. Cell count was measured with Scepter Cell Counter (Millipore), 60 ?m 
sensor and grating from 13 to 31 ?m and 6 to 20 ?m for FIB and Neuroblastoma respectively. Cell count 
was performed in triplicate. Protein concentration was measured using the bicinchoninic acid (BCA) 
protein assay (AppliChem). 10 ?l of sample was added to 190 ?l of BCA solution. A 3x BSA dilution 
standard starting at 1.5 mg/ml was used as reference. The samples were incubated 30 min at 37 °C. The 
assay was performed in a transparent Greiner 96-well plate and absorbance measured at 560 nm with a 
Tecan Infinite M1000 spectrophotometer. 
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 Dilution step D1 D2 D3 D4 D5 
F
IB
 
Cell count [-] 261205 183064 92701 43939 15533 
Cell count deviation 3640.962 11527.17 3701.147 9078.252 2488.685 
Protein concentration [?g/ml] 230.1759 140.5078 53.75903 37.51295 13.09721 
Protein concentration dev 2.960035 0.74614 0.422329 0.489173 0.1421 
N
e
u
ro
b
la
st
. Cell count [-] 359779 178542 106043 74144 36687 
Cell count deviation 840.0389 639.85 493.1453 1756.162 467.4495 
Protein concentration [?g/ml] 75.40909 51.70722 12.79547 12.27656 1.673821 
Protein concentration dev 2.357113 5.382547 0.054777 0.540845 0.015922 
Table 8 Conversion table from cells to protein content in FIB and neuoblastoma. For each cell concentration 3 
measurements were made and total resulting protein concentration was calculated by means of BCA assay.  
 
4.11 Chemical Synthesis 
Reaction conditions All reactions were carried in oven dried glassware at room temperature. All 
FMOC-NH-EGn-COOH (8, 15, 21) were purchased (PurePEG). APT (3) was purchased from TCL and N-1-
Fmoc-1,6-diaminohexane (4) was purchased from Fluorochem. Anhydrous DMSO was from Acros. 
Purchased chemicals and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Merck, Alfa 
Aesar or Acros and were not analyzed or further purified before usage.  
Purification Reaction mixtures were purified by reverse-phase preparative HPLC (HPLC-prep) on a 
Dionex system equipped with an UltiMate 3000 pump and an UV D170U UV-Vis detector for product 
visualization on a Waters SunFire Prep C18 OBD 5 ?m 19×150 mm column. Typical gradient was 
H2O/ACN 90:10 to 0:100 in 30 minutes at 4 ml/min. Fractions were automatically collected using Dionex 
UltiMate 3000 fraction collector. The system was operated by the Chromeleon 6.8 software.  
Lyophilization Solutions of ACN and water were frozen in liquid nitrogen and placed in round bottom 
flasks. The flask was connected to an alpha 1-2 LD plus lyophilizer connected to a Vacubrand RC6 pump 
and a gaz trap and left to sublimate overnight. 
NMR analysis Proton NMR spectra were recorded at room temperature on a Bruker Avance-III 400 
or on a Bruker DRX-600 equipped with a cryoprobe, with chemical shifts (?) reported in ppm relative to 
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the solvent residual signals. DMSO-d6: ?H 2.5 ppm; CD3OD: ?H 3.31 ppm. Coupling constants are 
reported in Hz. 
Routine compound analysis: Reaction progress and compound purity was assessed by LC-MS on a 
Nexera X2 Shimadzu system. The mass spectrometer was a LCMS 2020 module and both systems were 
connected via a FCN 20AH2 valve. Compounds were separated on a Waters Aquity UPLC BEH C18 50X2.1 
mm column preceded by a Waters Vanguard cartridge. Typical gradient was H2O/ACN 90:10 to 0:100 
within 6 minutes at 0.5 ml/min. Compounds were analyzed in positive mode. Hardware was operated via 
Shimadzu LabSolution software.  
4.11.1 General Procedures 
Amide bond formation Amide bond formation was performed first by activation of the respective 
carboxylic acid with N,N-diisopropylethylamine (DIPEA) and O-(N-succinimidyl)-N,N,N,N’-
tetramethyluronium tetrafluoroborate (TSTU) in dry DMSO. Routinely, were prepared as separate DMSO 
solutions: (i) 50 mM to 100 mM carboxylic acid starting material with 10 eq DIPEA; (ii) 0.1 mg/ml TSTU 
and (iii) 0.1 mg/ml amine bearing compound. A volume of TSTU solution corresponding to 1eq is added 
to the reaction mixture and stirred. Carboxylic acid activation was followed by LC-MS by looking for a 
compound of additional 98 g/mol with respect to the starting material. A volume of amine bearing 
solution corresponding to 1.1 eq is added to the activated reaction mixture and stirred further. The 
coupling was followed by LC-MS until completion. The reaction mixture was quenched by the addition of 
1 volume of water and 12 equivalent of AcOH. The reaction mixture was purified by HPLC-prep. The 
fractions were collected, combined and lyophilized overnight.  
FMOC deprotection Dry compounds were dissolved in DMF to 50 to 100 mM. 20% v/v of piperidine was 
added and the reaction mixture was stirred. The deprotection was followed by LC-MS until completion. 1 
volume of water and 2 equivalent of AcOH are added to precipitate the 1-((9H-fluoren-9-
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yl)methyl)piperidine. The solution is centrifuged for 3 minutes at 20000 rpm and the supernatant is 
collected. The collected supernatant is purified by HPLC-prep and lyophilized. 
Tert-butyl and methyl deprotection The dry product is dissolved in a solution of 1:1 water MeOH as a 50 
mM solution. 20% V/V of 1 M aq NaOH is added and the reaction mixture is stirred. The reaction is 
followed by LC-MS until completion. 2 equivalent of AcOH are added. The product is purified by HPLC-
prep and lyophilized as previously explained.  
4.11.2 MTX and APT Derivatives 
 
Synthesis of MXT-(CH2)10-NH2 (2) tBu protected MXT-(CH2)10-NH2 (1) was a gift from Dr. Stefan Pitsch. 
Purity of 1 was assessed by LC-MS before usage. The compound (17 mg, 25.6 ?mol) was deprotected 
according to the tert-butyl deprotection procedure (a). The resulting MXT-(CH2)10-NH2 (2, 82%, 12.4 mg) 
was analyzed by mass spectrometry and NMR. 1H NMR (400 MHz, DMSO-d6) ? 12.50 (s, 1H), 9.23 (s, 
1H), 9.02 (s, 1H), 8.72 (s, 1H), 8.54 (s, 1H), 8.31 (d, J = 7.5 Hz, 1H), 8.00 (s, 1H), 7.86 – 7.70 (m, 3H), 6.87 – 
6.80 (m, 2H), 4.88 (s, 2H), 4.29 (ddd, J = 9.5, 7.4, 4.8 Hz, 1H), 3.26 (s, 3H), 3.01 (q, J = 6.6 Hz, 2H), 2.84 – 
2.71 (m, 2H), 2.55 (s, 1H), 2.19 (t, J = 7.8 Hz, 2H), 2.13 – 2.00 (m, 1H), 1.92 (ddt, J = 13.9, 9.2, 7.2 Hz, 1H), 
1.51 (p, J = 7.3 Hz, 2H), 1.37 (s, 1H), 1.24 (d, J = 13.2 Hz, 14H). HDMS (ESI): 609.3617 m/z, exp Em: 
608.3547 m/z 
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Synthesis of APT-(CH2)6-NH2 (6) APT (3, 14 mg, 31.8 ?mol) and NH2-(CH2)6-NH-FMOC (4, 10.7 mg, 31.8 
?mol) were coupled according to the amide bond formation procedure (b) to yield APT-(CH2)6-NH-FMOC 
(5, 65%, 15.7 mg, 20.6 ?mol). The purity was assessed by LC-MS and no further analysis was performed. 
yield APT-(CH2)6-NH-FMOC (5, 15.7 mg, 20.6 ?mol) FMOC protecting group was removed via the FMOC 
deprotection procedure (c) to yield APT-(CH2)6-NH2 (6, 97%, 10.8 mg, 20 ?mol). The compound was 
analyzed by mass spectrometry and NMR. 1H NMR (600 MHz, DMSO-d6) ? 13.15 (s, 1H), 12.36 (s, 1H), 
9.17 (s, 2H), 8.83 (s, 1H), 7.86 (t, J = 5.7 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 4.61 (s, 
2H), 4.38 – 4.26 (m, 1H), 3.05 – 3.00 (m, 2H), 2.77 (t, J = 6.8 Hz, 3H), 2.19 (s, 1H), 1.92 (h, J = 7.1, 6.1 Hz, 
1H), 1.52 (dp, J = 22.1, 7.7, 6.7 Hz, 3H), 1.37 (dd, J = 14.4, 7.0 Hz, 3H), 1.26 (ddt, J = 20.2, 14.2, 6.5 Hz, 7H). 
HDMS (ESI): 539.2839 m/z, exp Em: 538.2764 m/z 
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4.11.3 Linkers and Control Linkers 
Synthesis of BG-EG2-TMR-C6-APT and BG-EG5-TMR-C6-APT 
 
 
Synthesis of BG-EG2-NH2 (10): BG (7) was a gift from Dr. Luc Reymond and purity was analyzed by LC-MS 
before usage. NH2-EG2-NH-FMOC (8, 4.39 mg, 11 ?mol) and BG (7, 3 mg, 11 ?mol) were coupled 
according to the amide bond formation procedure (d). BG-EG2-NH-FMOC (9, 91%, 6.4 mg, 10.1 ?mol) 
was recovered and deprotected according to the FMOC deprotection procedure (e). BG-EG2-NH2 (10, 
98%, 9.9 ?mol) was recovered and analyzed. BG-EG2-NH2 NMR 1H NMR (600 MHz, DMSO-d6) ? 8.35 (t, J 
= 6.2 Hz, 1H), 8.27 (s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 5.51 (s, 2H), 4.33 (d, J = 6.2 Hz, 
2H), 3.97 (s, 2H), 3.59 (t, J = 5.3 Hz, 4H), 2.97 (h, J = 5.6 Hz, 2H). MS (ESI) : 416.1 m/z (M+1) 
Synthesis of BG-EG2-TMR-COOH (13): TMR (11) was a gift from Dr. Lin Xue and was analyzed by NMR and 
LC-MS. TMR (11, 4.6 mg, 8.8 ?mol) and BG-EG2-NH2 (10, 4.1 mg, 9.77 ?mol) were coupled according to 
the amide bond formation procedure (f). BG-EG2-TMR-COOMe (12, 60%, 4.7 mg, 5.2 ?mol) was 
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recovered and deprotected according to the methyl deprotection procedure (g). BG-EG2-TMR-COOH (13, 
quantitative, 5.1 ?mol) was recovered and analyzed. Half of the quantity was kept as control ligand for 
later experiments. TMR (11) 1H NMR (400 MHz, Methanol-d4) ? 8.47 – 8.36 (m, 2H), 8.00 (d, J = 1.5 Hz, 
1H), 7.16 (dd, J = 9.5, 2.0 Hz, 2H), 7.13 – 6.99 (m, 3H), 6.97 (d, J = 2.4 Hz, 1H), 3.70 (s, 1H), 3.68 (s, 4H), 
3.31 (s, 6H), 3.28 (s, 3H), 2.47 (t, J = 6.8 Hz, 2H), 1.99 (p, J = 7.0 Hz, 2H). BG-EG2-TMR-COOH (13) 1H NMR 
(600 MHz, DMSO-d6) ? 8.37 – 8.10 (m, 4H), 7.89 (s, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.26 (d, J = 7.7 Hz, 2H), 
7.15 – 6.90 (m, 6H), 5.46 (s, 2H), 4.27 (d, J = 6.2 Hz, 2H), 3.64 (d, J = 8.7 Hz, 2H), 3.54 (t, J = 6.0 Hz, 3H), 
3.43 (d, J = 5.7 Hz, 1H), 3.00 (d, J = 1.3 Hz, 1H), 2.45 (s, 3H), 2.34 (s, 1H), 2.19 (s, 1H), 1.82 (s, 2H).HDMS 
(ESI): 900.3675 m/z, exp Em: 900.3681 m/z 
Synthesis of BG-EG2-TMR-(CH2)6-APT (14): BG-EG2-TMR-COOH (13, 2.3 mg, 2.6 ?mol) and APT-(CH2)6-NH2 
(7, 1.5 mg, 2.8 ?mol) were coupled according to the amide bond formation procedure (h). BG-EG2-TMR-
(CH2)6-APT (14, 12%, 0.5 mg, 0.4 ?mol) was recovered and analyzed. BG-EG2-TMR-(CH2)6-APT 1H NMR 
(600 MHz, DMSO-d6) 8.91 – 8.78 (m, 2H), 8.31 – 8.23 (m, 3H), 7.88 (s, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.45 
(d, J = 7.8 Hz, 2H), 7.26 (d, J = 7.7 Hz, 2H), 7.12 – 6.99 (m, 5H), 6.96 (d, J = 8.6 Hz, 1H), 6.75 (d, J = 8.3 Hz, 
2H), 5.46 (s, 2H), 4.62 (s, 2H), 4.40 – 4.32 (m, 1H), 4.27 (d, J = 6.2 Hz, 2H), 3.91 (s, 2H), 3.56 (d, J = 27.3 Hz, 
8H), 3.24 (d, J = 21.8 Hz, 11H), 3.01 (dq, J = 19.9, 6.9 Hz, 4H), 2.39 (t, 2H), 2.17 (dd, J = 12.2, 6.8 Hz, 4H), 
1.87 – 1.77 (m, 2H), 1.41 – 1.30 (m, 4H), 1.29 – 1.15 (m, 4H). HDMS (ESI): 1420.6340 m/z, exp Em: 
1420.6339 m/z 
 
Synthesis of BG-EG5-NH2 (17): NH2-EG5-NH-FMOC (15, 5.74 mg, 11 ?mol) and BG (7, 3 mg, 11 ?mol) were 
coupled according to the amide bond formation procedure (d). BG-EG5-NH-FMOC (16, 91%, 5.8 mg, 10.1 
?mol) was recovered and deprotected according to the FMOC deprotection procedure (e). BG-EG5-NH2 
(17, quantitative, 10 ?mol) was recovered and analyzed by NMR. BG-EG5-NH2 1H NMR (600 MHz, DMSO-
d6) ? 8.32 (t, J = 6.2 Hz, 1H), 8.20 (s, 1H), 7.51 – 7.46 (m, 2H), 7.30 (d, J = 8.1 Hz, 2H), 5.50 (s, 2H), 4.33 (d, 
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J = 6.2 Hz, 2H), 3.96 (s, 2H), 3.64 – 3.54 (m, 14H), 3.56 – 3.46 (m, 4H), 2.98 (p, J = 5.6 Hz, 2H), 2.61 – 2.52 
(m, 2H). MS (ESI): 548.2 m/z (M+1) 
Synthesis of BG-EG5-TMR-COOH (13): TMR (11, 3 mg, 5.8 ?mol) and BG-EG5-NH2 (10, 3.5 mg, 6.3 ?mol) 
were coupled according to the amide bond formation procedure (f). BG-EG5-TMR-COOMe (12, 86%, 4.5 
mg, 5 ?mol) was recovered and deprotected according to the methyl deprotection procedure (g). BG-
EG5-TMR-COOH (13, quantitative, 5 ?mol) was recovered and analyzed. Roughly half of the quantity was 
kept as control ligand for later experiments (L5C). BG-EG5-TMR-COOH (13) 1H NMR (600 MHz, DMSO-d6) 
? 8.87 (t, J = 5.7 Hz, 1H), 8.36 – 8.21 (m, 3H), 7.92 – 7.86 (m, 1H), 7.47 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 7.9 
Hz, 2H), 7.17 – 6.98 (m, 5H), 6.96 (d, J = 2.3 Hz, 1H), 5.48 (s, 2H), 4.31 (d, J = 6.3 Hz, 2H), 3.93 (s, 2H), 3.62 
(s, 7H), 3.58 (s, 15H), 3.27 (s, 6H), 3.24 (s, 3H), 2.34 (t, J = 7.1 Hz, 2H), 1.83 (q, J = 7.5 Hz, 2H). HDMS (ESI): 
1032.4463 m/z, exp Em : 1032.4467 m/z 
Synthesis of BG-EG5-TMR-(CH2)6-APT (14, L5): BG-EG5-TMR-COOH (13, 1.8mg, 2?mol) and APT-(CH2)6-NH2 
(7, 1.2 mg, 2.2 ?mol) were coupled according to the amide bond formation procedure (h). BG-EG5-TMR-
(CH2)6-APT (14, 32%, 1 mg, 0.6 ?mol) was recovered and analyzed. BG-EG5-TMR-(CH2)6-APT 1H NMR (600 
MHz, DMSO-d6) ? 8.80 (d, J = 23.0 Hz, 3H), 8.31 – 8.08 (m, 6H), 7.92 – 7.66 (m, 7H), 7.43 (d, J = 7.7 Hz, 
2H), 7.27 (d, J = 7.7 Hz, 2H), 6.75 (d, J = 7.9 Hz, 2H), 5.43 (s, 2H), 4.59 (s, 2H), 4.31 (d, J = 6.2 Hz, 2H), 3.92 
(d, J = 13.0 Hz, 2H), 3.60 – 3.56 (m, 6H), 3.54 (d, J = 4.4 Hz, 1H), 3.02 – 2.94 (m, 1H), 2.20 (q, J = 7.7 Hz, 
1H), 2.13 (s, 2H), 1.78 (d, J = 27.8 Hz, 2H), 1.29 – 1.16 (m, 8H).HDMS (ESI): 1552.7120 m/z, exp Em : 
1552.7126 m/z 
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Synthesis of BG-EG11-TMR-C6-APT  
 
 
Synthesis of BG-EG11-NH2 (23): NH2-EG11-NH-FMOC (21, 3.9 mg, 4.9 ?mol) and BG (7, 1.5 mg, 5.4 ?mol) 
were coupled according to the amide bond formation procedure (d). BG-EG11-NH-FMOC (22, 88%, 3.7 
mg, 4.3 ?mol) was recovered and deprotected according to the FMOC deprotection procedure (e). BG-
EG5-NH2 (23, 97%, 3.7 mg, 4.2 ?mol) was recovered and analyzed. BG-EG11-NH2 1H NMR (600 MHz, 
DMSO-d6) ? 8.42 (t, J = 5.9 Hz, 1H), 8.28 (s, 1H), 7.53 – 7.41 (m, 2H), 7.36 – 7.26 (m, 2H), 5.51 (s, 2H), 
4.28 (d, J = 5.9 Hz, 2H), 3.67 – 3.53 (m, ~4H), 3.53 – 3.44 (m, ~44H), 3.11 (q, J = 6.3, 5.8 Hz, 2H), 2.40 – 
2.36 (m, 2H).MS (ESI): 435.8 m/z (M2+) 
Synthesis of BG-EG11-TMR-COOH (25): TMR (11, 2.1 mg, 4.1 ?mol) and BG-EG11-NH2 (23, 3.6 mg, 4.1 
?mol) were coupled according to the amide bond formation procedure (f). BG-EG11-TMR-COOMe (24, 
76%, 4.2 mg, 3.1 ?mol) was recovered and deprotected according to the methyl deprotection procedure 
(g) the compound was analyzed by HDMS and HNMR. BG-EG11-TMR-COOH (25, quantitative, 3.1 ?mol) 
- 104 - 
 
was recovered and not further characterized. Roughly half of the quantity was kept as control ligand for 
later experiments (L11C). BG-EG11-TMR-COOMe 1H NMR (400 MHz, DMSO-d6) ? 8.83 (t, J = 5.6 Hz, 1H), 
8.36 (t, J = 5.9 Hz, 1H), 8.33 – 8.21 (m, 2H), 7.88 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 
Hz, 2H), 7.13 – 7.00 (m, 5H), 6.97 (d, J = 2.3 Hz, 1H), 5.48 (s, 2H), 4.27 (d, J = 5.9 Hz, 2H), 3.59 (s, 3H), 3.52 
– 3.47 (m, ~4H), 3.47 – 3.44 (m, ~44H), 3.27 (s, 6H), 3.23 (s, 3H), 2.38 (t, J = 6.4 Hz, 2H), 1.96 – 1.76 (m, 
2H).HDMS (ESI): 1368.6610 m/z, exp Em : 1368.6615 m/z 
Synthesis of BG-EG11-TMR-(CH2)6-APT (25, L11): BG-EG11-TMR-COOH (25, 1.5 mg, 1.1 ?mol) and APT-
(CH2)6-NH2 (7, 0.7 mg, 1.2 ?mol) were coupled according to the amide bond formation procedure (h). BG-
EG11-TMR-(CH2)6-APT (25, 13%, 0.26 mg, 0.14 ?mol) was purified, lyophilized and analyzed. EG11-TMR-
(CH2)6-APT 1H NMR (600 MHz, DMSO-d6) ? 8.79 (d, J = 28.2 Hz, 2H), 8.39 (s, 3H), 7.68 (s, 1H), 7.63 (d, J = 
8.4 Hz, 1H), 7.45 (d, J = 7.8 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 6.85 – 6.72 (m, 6H), 6.66 (s, 2H), 5.45 (s, 2H), 
4.49 (s, 2H), 4.27 (d, J = 5.9 Hz, 3H), 3.63 (t, J = 6.3 Hz, 2H), 3.55 – 3.46 (m, ~48H), 3.33 – 3.28 (m, 9H), 
2.95 (s, 2H), 2.92 (d, J = 8.6 Hz, 2H), 2.37 (d, J = 6.3 Hz, 2H), 2.09 (t, J = 7.0 Hz, 2H), 1.70 (d, J = 8.0 Hz, 2H), 
1.36 – 1.31 (m, 4H), 1.26 – 1.19 (m, 4H). HDMS (ESI): 1874.9111 m/z, exp Em : 1874.9117 m/z 
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Appendix: Amino Acid Sequences 
DHPR : 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGAPGFS
SISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Red : hDHPR 
SNAP-DHPR : 
MASWSHPQFEKGADDDDKVPHMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLN
AYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGL
AVKEWLLAHEGHRLGKPGLGGGSGGSMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGAPGFS
SISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR 
DHPR-SNAP: 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGGSGGS
MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESF
TRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGLAVKEWLLAHEGHRLGKPGLGGAPGFS
SISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR. 
SNAP-Pro30-DHPR 
MASWSHPQFEKGADDDDKVPHMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLN
AYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGL
AVKEWLLAHEGHRLGKPGLGEFPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPGGSGGSMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARN
WWVASVDVVENEEASASIIVKMTDSFTEQADQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLK
EGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGK
NRPSSGSLIQVVTTEGRTELTPAYFGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer. 
DHPR-Pro30-SNAP: 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VH3QLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGGSGG
SPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPGGRSRSLEMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPE
PLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQG
DLDVGGYEGGLAVKEWLLAHEGHRLGKPGLGGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer. 
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DHPR-HALO-Pro30-SNAP: 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VH3QLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGSEIGT
GFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEV
VLVIHDWGSALGFHWAKRNPERVKGIAFMEFIRPIPTWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREPFL
NPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPKLLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARW
LSTLEISGGGSGGSPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPGGRSRSLEMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVE
VPAPAAVLGGPEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNP
VPILIPCHRVVQGDLDVGGYEGGLAVKEWLLAHEGHRLGKPGLGGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer, Grey : HALO. 
SNAP-Pro30-HALO-DHPR 
MASWSHPQFEKGADDDDKVPHMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLN
AYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGL
AVKEWLLAHEGHRLGKPGLGGRPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPGGSEIGTGFPFDPHYVEVLGERMHYVDVGPRDGTPVLFLHGN
PTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVIHDWGSALGFHWAKRNPERVKGIAFMEFIRPIP
TWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREPFLNPVDREPLWRFPNELPIAGEPANIVALVEEYMDWLH
QSPVPKLLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTLEISGGGSGGSMAAAAAAGEARRVLVYGGRGAL
GSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQADQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIW
TSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLE
FLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer. 
DHPR-HALO[4:]-Pro30-SNAP: 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VH3QLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGTGFP
FDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVI
HDWGSALGFHWAKRNPERVKGIAFMEFIRPIPTWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREPFLNPV
DREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPKLLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTL
EISGPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPGGRSRSLEMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGG
PEPLMQATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQ
GDLDVGGYEGGLAVKEWLLAHEGHRLGKPGLGGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer, Grey : HALO. 
DHPR-HALO[4:]-Pro15-SNAP: 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VH3QLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGTGFP
FDPHYVEVLGERMHYVDVGPRDGTPVLFLHGNPTSSYVWRNIIPHVAPTHRCIAPDLIGMGKSDKPDLGYFFDDHVRFMDAFIEALGLEEVVLVI
HDWGSALGFHWAKRNPERVKGIAFMEFIRPIPTWDEWPEFARETFQAFRTTDVGRKLIIDQNVFIEGTLPMGVVRPLTEVEMDHYREPFLNPV
DREPLWRFPNELPIAGEPANIVALVEEYMDWLHQSPVPKLLFWGTPGVLIPPAEAARLAKSLPNCKAVDIGPGLNLLQEDNPDLIGSEIARWLSTL
EISGPPPPPPPPPPPPPPPGGRSRSLEMDKDCEMKRTTLDSPLGKLELSGCEQGLHEIIFLGKGTSAADAVEVPAPAAVLGGPEPLMQATAWLNA
YFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYSHLAALAGNPAATAAVKTALSGNPVPILIPCHRVVQGDLDVGGYEGGLA
VKEWLLAHEGHRLGKPGLGGAPGFSSISAHHHHHHHHHH 
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Violet : purification tags ( Strep-Tag, His10-Tag); Green : SNAP-Tag; Orange : Flexible (GGS)n linker, Red : hDHPR, Cyan : 
Pro30 spacer, Grey : HALO. 
DHPR(E46X) 
MASWSHPQFEKGADDDDKVPHMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENXEASASIIVKMTDSFTEQA
DQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGA
VHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGAPGFS
SISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Red : hDHPR 
cpDHPR 
MASWSHPQFEKGADDDDKVPHEASASIIVKMTDSFTEQADQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSI
WTSTISSHLATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAIAVLPVTLDTPMNRKSMPEADFSSWTP
LEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELTPAYFGGSGGSGGSGGSMAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASV
DVVENEGAPGFSSISAHHHHHHHHHH 
Violet : purification tags ( Strep-Tag, His10-Tag); Red : hDHPR; Orange : Flexible (GGS)n linker 
All constructs containing cpDHPR or DHPRE(E46X) had DHPR replaced with the respective sequence 
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Appendix: protein gels and yields 
DHPR SNAP-DHPR 
 
 
Three last bands are final fractions. 
Yield: 3.9mg / L 
 
Two last bands are final fractions. 
Yield: 2.7mg / L 
DHPR-SNAP DHPR-P30-SNAP 
 
 
Two last bands are final fractions. 
Yield: 3.2mg / L 
Two last bands are final fractions. 
Yield: 3.1mg / L 
DHPR-Halo-P30-SNAP cpDHPR 
  
Last band on the right is the final fraction. 
Yield 1.2mg / L 
 
The two last bands on the right are the final 
fractions. 
Yield: 4mg / L 
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DHPR-Halo[4:]-p30-SNAP cpDHPR-ggs-Halo-p30-SNAP 
  
 
Last band on the right is the final fraction. 
Yield 5mg / L 
Last band on the right is the final fraction. 
Yield 0.7mg / L 
cpDHPR-Halo-p30-SNAP cpDHPR-Halo[4:]-p30-SNAP 
  
Last band on the right is the final fraction. 
Yield 0.55mg / L 
Last band on the right is the final fraction. 
Yield 0.8mg / L 
SNAP-DHPR labeling DHPR-SNAP labeling 
 
Ypc3 is SNAP-DHPR. “pur.” is sample after centrifugal 
filtration 
Ypc4 is DHPR-SNAP. “pur.” is sample after 
centrifugal filtration 
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DHPR-P30-Halo[4:]-SNAP DHPR-P30-SNAP labeling 
 
 
Sensor + L11 (1), filtered (2), with BG-Alexa488 (3) 
Sensor + L11 & Sir-HaloTag(4), filtered (5), with BG-
Alexa488 (6), with CPY-HaloTag(7). Was used for screening 
“pur.” is the sample after centrifugal filtration 
YpC 18 is cpDHPR-ggs2-Halo-P30-SNAP 
YpC 19 is cpDHPR-Halo-P30-SNAP 
YpC 20 is cpDHPR Halo[4:]-P30-SNAP 
 
 
 
+ w is after centrifugal filtration 
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Appendix: Structures of the Hits 
 
 
Daunorubicin 
 
 
 
Doxorubicin 
 
 
Epirubicin 
 
 
 
Tetraethylene-
pentamine 
 
 
Pentetic acid 
 
 
 
Ebselen 
 
 
Triamterene 
Mitoxantrone 
 
 
Deoxycorticosterone 
 
 
Zaprinast 
 
 
Adrenosterone 
 
 
Corticosterone 
 
 
 
Praziquantel 
 
Etomidate  
Etifenin 
 
 
Progesterone 
 
 
Oxytetracycline 
 
 
Medrysone 
 
 
Mizolastine 
 
 
Alexidine 
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Exemestane 
 
 
 
 
 
Sulfadimethoxine 
 
 
Paclitaxel 
 
 
Clofazimine 
 
 
 
Methotrexate  
 
Testosterone propionate 
 
 
Bephenium hydroxy- 
naphtoate 
 
 
Carbenoxolone 
 
 
 
Benserazide 
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